

1 Null effects of levodopa on reward- and 2 error-based motor adaptation, savings, and 3 anterograde interference 4

5 Dimitrios J. Palidis ^{1,2,3}, Heather R. McGregor ⁴, Andrew Vo ⁵, Penny A. MacDonald
6 ^{1,2,3,6,7 #}, Paul L. Gribble ^{1,2,6,8 # *}

- 7
- 8 1. The Brain and Mind Institute, Western University, London, ON, N6A 57B, Canada
- 9 2. Dept. Psychology, Western University, London, ON, N6A 5C2, Canada
- 10 3. Graduate Program in Neuroscience, Schulich School of Medicine & Dentistry, Western University, London, ON,
11 N6A 3K7, Canada
- 12 4. Dept. of Applied Physiology and Kinesiology, University of Florida, Gainesville, FL, USA
- 13 5. Dept. of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, H3A
14 2B4, Canada
- 15 6. Dept. Physiology & Pharmacology, Schulich School of Medicine & Dentistry, Western University, London, ON,
16 N6A 5C1 Canada
- 17 7. Dept. of Clinical Neurological Sciences, University of Western Ontario, London, ON, N6A 5A5, Canada
- 18 8. Haskins Laboratories, New Haven, CT, 06511, USA

19
20 # Co-senior authors

21 * Corresponding author: Paul Gribble, pgribble@uwo.ca
22
23

24 **Author Contributions:** DJP, HRM, PAM, PLG designed research, DJP, AV performed
25 research, DJP analyzed data, DJP wrote the paper, DJP, HRM, AV, PAM, PLG edited
26 the paper.
27

28 Authors report no conflict of interest.
29

30 **Funding sources:** This work was supported by the Natural Science and Engineering
31 Council of Canada (RGPIN-2018-05458 to PLG and RGPIN-2019-i07300 to PAM) and
32 the Canada Research Chair program (PAM). DJP was supported by a graduate
33 scholarship from NSERC. HRM was supported by a NSERC postdoctoral fellowship.
34

35 **Abbreviated Title:** Null effects of levodopa on motor adaptation
36

37 **Keywords:** motor adaptation, reward, reinforcement, FRN, reward positivity, dopamine

38 **Abstract**

39
40 Dopamine signaling is thought to mediate reward-based learning. We tested for a role of
41 dopamine in motor adaptation by administering the dopamine precursor levodopa to
42 healthy participants in two experiments involving reaching movements. Levodopa has
43 been shown to impair reward-based learning in cognitive tasks. Thus, we hypothesized
44 that levodopa would selectively impair aspects of motor adaptation that depend on
45 reinforcement of rewarding actions.

46
47 In the first experiment, participants performed two separate tasks in which adaptation
48 was driven either by visual error-based feedback of the hand position or binary reward
49 feedback. We used EEG to measure event-related potentials evoked by task feedback.
50 We hypothesized that levodopa would specifically diminish adaptation and the neural
51 responses to feedback in the reward learning task. However, levodopa did not affect
52 motor adaptation in either task nor did it diminish event-related potentials elicited by
53 reward outcomes.

54
55 In the second experiment, participants learned to compensate for mechanical force field
56 perturbations applied to the hand during reaching. Previous exposure to a particular
57 force field can result in savings during subsequent adaptation to the same force field or
58 interference during adaptation to an opposite force field. We hypothesized that levodopa
59 would diminish savings and anterograde interference, as previous work suggests that
60 these phenomena result from a reinforcement learning process. However, we found no
61 reliable effects of levodopa.

62
63 These results suggest that reward-based motor adaptation, savings, and interference
64 may not depend on the same dopaminergic mechanisms that have been shown to be
65 disrupted by levodopa during various cognitive tasks.

66 67 **New and Noteworthy**

68
69 Motor adaptation relies on multiple processes including reinforcement of successful
70 actions. Cognitive reinforcement learning is impaired by levodopa-induced disruption of
71 dopamine function. We administered levodopa to healthy adults who participated in
72 multiple motor adaptation tasks. We found no effects of levodopa on any component of
73 motor adaptation. This suggests that motor adaptation may not depend on the same
74 dopaminergic mechanisms as cognitive forms or reinforcement learning that have been
75 shown to be impaired by levodopa.

76 Introduction

77
78 Human motor control is adaptive to changes of the environment and the body through
79 multiple mechanisms including reinforcement of successful actions and recalibration of
80 internal mappings between motor commands and sensory outcomes (Huang et al.,
81 2011; Izawa & Shadmehr, 2011; J. A. Taylor et al., 2014; Wolpert et al., 1995). Two
82 prominent experimental models of motor adaptation are force field adaptation and
83 visuomotor rotation (VMR) tasks. In studies of force field adaptation, a robot applies
84 velocity-dependent forces to the hand during reaches to targets. In visuomotor rotation
85 tasks, a cursor on a digital display represents the position of the hand, and the mapping
86 between the actual reach angle and the position of the cursor is rotated. In both tasks
87 participants quickly adapt their movements to compensate for the experimentally
88 induced perturbations. Learning involves the cerebellum, and parietal, sensory, and
89 motor cortical areas (Diedrichsen et al., 2005; Ito, 2000; Krakauer et al., 2004; Smith &
90 Shadmehr, 2005; Tanaka et al., 2009; Jordan A. Taylor et al., 2010; Wong et al., 2019).
91 It is thought that these neural circuits predict the sensory consequences of motor
92 commands, and that adaptation occurs in response to sensory prediction error when
93 sensory afference violates these predictions (Adams et al., 2013; Bhanpuri et al., 2013;
94 Izawa & Shadmehr, 2011; R. Chris Miall et al., 2007; Shadmehr et al., 2010; Synofzik et
95 al., 2008; Therrien & Bastian, 2015; Tseng et al., 2007; Wolpert et al., 1995).

96
97 While sensory error-based learning mechanisms are dominant in typical motor
98 adaptation paradigms, influences of reinforcement learning processes are increasingly
99 recognized (Bernardi et al., 2015; Cashaback et al., 2019; Izawa & Shadmehr, 2011;
100 Kim et al., 2019; Kooij et al., 2018; McDougle et al., 2016; Mehler et al., 2017; Nikooyan
101 & Ahmed, 2014; Palidis et al., 2019; Sidarta et al., 2016, 2018; van der Kooij & Smeets,
102 2019). Reward and task success can modulate sensory error-based learning (Galea et
103 al., 2015; Kim et al., 2019; Kooij et al., 2018; Kuling et al., 2019; Leow et al., 2018,
104 2020; Shmuelof et al., 2012). Reinforcement learning and sensory error-based learning
105 can also contribute to adaptation as separable processes. Adaptation to sensory error
106 has been shown to occur automatically even when it interferes with task success
107 (Mazzoni & Krakauer, 2006). Reward-based adaptation can be isolated experimentally
108 by providing only binary reinforcement feedback indicating success or failure (Izawa &
109 Shadmehr, 2011; Shmuelof et al., 2012). When sensory error-based learning cannot
110 occur due to impoverished sensory feedback or cerebellar damage, reward-based
111 learning can produce comparable behavioral adaptation (Cashaback et al., 2017; Izawa
112 & Shadmehr, 2011; Therrien et al., 2016).

113
114 It is thought that reward prediction error drives biological reinforcement learning when
115 an action results in an outcome that is better or worse than expected (Daw & Tobler,
116 2014; Sambrook & Goslin, 2015; Walsh & Anderson, 2012). Phasic changes in the firing
117 rate of midbrain dopamine neurons match reward prediction error signals predicted by
118 computational models of reinforcement learning (Bayer & Glimcher, 2005; García-García et
119 al., 2017; Jocham & Ullsperger, 2009; Schultz et al., 1997; Watabe-Uchida et al., 2017). These
120 dopaminergic signals are thought to mediate synaptic plasticity in the striatum and

121 frontal cortex underlying reward-based learning (Otani et al., 2003; Reynolds &
122 Wickens, 2002; Wang et al., 2018).

123
124 Levodopa is a dopamine precursor commonly used to treat motor symptoms in patients
125 with Parkinson's disease. Levodopa has been shown to impair reward-based learning in
126 both patients and healthy participants (Cools et al., 2001, 2007; Feigin et al., 2003;
127 Frank et al., 2004; Graef et al., 2010; Hiebert et al., 2014; Jahanshahi et al., 2010; Kwak
128 et al., 2010; MacDonald et al., 2011; Swainson et al., 2000; Torta et al., 2009; Vo et al.,
129 2016, 2018). According to the "dopamine overdose" hypothesis, dopamine levels affect
130 performance in tasks that depend on the striatum according to an inverted-u function
131 (Cools et al., 2007). In early-stage Parkinson's disease, the dorsal striatum is
132 significantly depleted of dopamine whereas the ventral striatum is comparatively spared.
133 Dopaminergic therapy is predicted to ameliorate deficits caused by dopamine-depletion
134 in the dorsal striatum but to worsen functions ascribed to the ventral striatum. In line
135 with this view, reward-based learning is thought to rely on dopamine signaling in ventral
136 striatum and is impaired by levodopa.

137
138 Although dopamine is widely implicated in reward-based learning, it is not clear whether
139 this role extends to reward-based motor adaptation. We administered levodopa to
140 healthy young participants to test for effects on motor adaptation. In our first experiment,
141 participants received levodopa and placebo in separate sessions using a repeated
142 measures design. Both sessions included a reward-based learning task and a sensory
143 error-based VMR task. In the reward-based learning task, adaptation was induced
144 through binary reinforcement feedback at the end of each movement. We measured
145 changes in the mean reach angle due to reinforcement as well as modulations in trial-
146 by-trial variability of reach angle as a response to reward outcomes. Previous research
147 has shown that motor variability increases following unrewarded outcomes compared to
148 rewarded outcomes (Dhawale et al., 2019; Holland et al., 2018; Mastrigt et al., 2020;
149 Pekny et al., 2015; van der Kooij & Smeets, 2019). This could indicate reinforcement of
150 rewarded actions as well as exploration in response to unrewarded outcomes
151 (Cashaback et al., 2019; Dhawale et al., 2019). This variance modulation is impaired in
152 individuals with Parkinson's disease who are medicated, but it remains unclear whether
153 this deficit is caused by the disease process itself or side-effects of dopaminergic
154 medication (Pekny et al., 2015). We predicted that levodopa would impair reward-based
155 motor adaptation and modulation of trial-by-trial variability in accordance with the
156 "dopamine overdose hypothesis".

157
158 In the sensory error-based learning task, participants adapted to visuomotor rotation
159 perturbations designed to produce sensory prediction error while minimizing reward
160 prediction error. Investigations as to whether VMR learning depends on dopamine have
161 shown inconsistent results (Bédard & Sanes, 2011; Marinelli et al., 2009; Mongeon et al.,
162 2013; Noohi et al., 2014). Sensory error-based learning may be mediated by non-
163 dopaminergic mechanisms depending primarily on the cerebellum, whereas dopamine
164 affects VMR learning through additional or modulatory contributions of a reinforcement
165 learning process (Singh et al., 2019). We hypothesized that sensory error-based

166 learning would be unaffected by levodopa. As such, we designed our sensory error-
167 based learning task to preclude effects of reinforcement.

168
169 In experiment 1, we recorded EEG to measure neural event-related potentials (ERPs).
170 Previously, we found that a medial frontal ERP component called the feedback related
171 negativity, or alternatively the reward positivity (FRN/RP), was modulated by reward
172 feedback but not sensory error feedback during motor adaptation (Palidis et al., 2019).
173 This is consistent with a prominent theory stating that the FRN/RP reflects reward
174 prediction error signals driven by dopamine release (Becker et al., 2014; Carlson et al.,
175 2011; Emeric et al., 2008; Foti et al., 2011; Gehring & Willoughby, 2002; Hauser et al.,
176 2014; Holroyd et al., 2008; Holroyd & Coles, 2002; Mathewson et al., 2008; Miltner et
177 al., 1997; Sambrook & Goslin, 2015, 2016; Vezoli & Procyk, 2009; Walsh & Anderson,
178 2012; Warren et al., 2015). However, direct evidence for a link between dopamine and
179 the FRN/RP is fairly limited, and no studies have investigated this link in the context of
180 motor adaptation (Enge et al., 2017; Forster et al., 2017; Marco-Pallarés et al., 2009; Mueller
181 et al., 2014; Santesso et al., 2009; Schutte et al., 2020). We hypothesized that levodopa
182 would diminish the magnitude of the FRN/RP along with behavioral expression of
183 reward-based learning in accordance with the “dopamine overdose” hypothesis.

184
185 In experiment 2, participants ingested either levodopa or placebo prior to performing a
186 force field adaptation task. We tested for effects of levodopa on savings, in which
187 adaptation is facilitated when a particular perturbation is encountered a second time
188 after washout of initial learning. We also tested for effects of levodopa on anterograde
189 interference, in which adaptation to a force field in a particular direction causes
190 interference with subsequent adaptation to an opposite-direction force field (Bock et al.,
191 2001; Huang et al., 2011; Leow et al., 2012, 2013; R. Christopher Miall et al., 2004;
192 Sing & Smith, 2010). While force field adaptation is thought to rely primarily on sensory
193 error-based learning mechanisms, savings and anterograde interference can be
194 accounted for by additional influences of a reinforcement learning process (Huang et al.,
195 2011). Individuals with Parkinson's disease show reduced savings and interference
196 despite intact initial adaptation (Bédard & Sanes, 2011; Leow et al., 2012, 2013). While
197 these results suggest a role of dopamine in savings and interference, they typically don't
198 distinguish between effects of Parkinson's disease and side-effects of medication. We
199 used pharmacological manipulation in healthy participants to provide a more specific
200 and controlled test for a role of dopamine in savings and interference. We predicted that
201 levodopa would impair savings and interference while leaving initial adaptation
202 unaffected.

203
204 We tested for effects of levodopa using a comprehensive battery of motor adaptation
205 tasks. This allowed us to test the hypotheses that dopaminergic mechanisms
206 specifically underlie adaptive motor responses to reward outcomes as well as the
207 formation of motor memories that produce savings and interference effects. We also
208 measured the FRN/RP, a common neural correlate of reward prediction error. This
209 allowed us to test the hypothesis that dopaminergic signaling of reward prediction error
210 in the medial frontal cortex drives reward-based motor adaptation.

211

212 **Methods**

213

214 **Experiment 1**

215

216 ***Participants***

217

218 A total of $n=21$ [12 female, Age: 20.99 years (SD 3.26)] healthy, right-handed
219 participants were included in experiment 1. All participants were screened for
220 neurological and psychiatric illness, history of drug or alcohol abuse, and
221 contraindications for levodopa. Two participants were excluded due to malfunction of
222 the robot that prevented the experiment from being completed, and two participants
223 were excluded who did not return for the second testing session. Participants provided
224 written informed consent to experimental procedures approved by the Research Ethics
225 Board at Western University.

226

227 ***Experimental design***

228

229 *Drug administration:* All participants underwent two experimental sessions, with
230 levodopa and placebo being administered in separate sessions using a randomized,
231 double-blind, crossover design. The two sessions were separated by a washout period
232 of at least one week. In one session, a capsule was ingested that contained 100 mg of
233 levodopa (L-3,4-dihydroxyphenylalanine) and 25 mg of carbidopa. Levodopa is a
234 dopamine precursor, and carbidopa is a decarboxylase inhibitor given to reduce
235 conversion of levodopa to dopamine in the periphery. This dose has been shown to
236 produce various behavioral effects in healthy young adults (Flöel et al., 2005; Knecht et al.,
237 2004; Onur et al., 2011; Vo et al., 2016, 2017, 2018). In the other session, an equal volume
238 of placebo was administered in an identical capsule. The order of administration was
239 counterbalanced. After administration of the capsule, the robot was calibrated, the EEG
240 cap was placed on the participant's head, and participants performed a practice block of
241 the behavioral task (see below). Subsequently, the experimental tasks began 45
242 minutes after ingestion of the capsule to coincide with peak plasma levels of levodopa
243 (Olanow et al., 2000). We measured heart rate, blood pressure, and subjective
244 alertness immediately prior to ingestion of placebo or levodopa and again at the end of
245 each session. Alertness was assessed using the Bond-Lader visual analog scale (Bond
246 & Lader, 1974).

247

248 *Overview of behavioral tasks:* Each participant underwent the same experimental tasks
249 in both sessions. Participants made reaching movements toward a visual target and
250 received visual feedback pertaining to reach angle only at movement end point (figure
251 1). Neural responses to feedback were recorded using EEG. Participants were
252 instructed that each reach terminating within the target would be rewarded with a small
253 monetary bonus. Participants first performed a block of 50 practice trials. The
254 subsequent behavioral procedure consisted of two blocks of a reward learning task and
255 two blocks of a visuomotor rotation (VMR) task. The order of the blocks alternated
256 between the two task types but was otherwise randomized. Participants took self-paced
257 rests between blocks.

258
259 In the VMR task, a cursor appeared at movement end point to represent the position of
260 the hand (Figure 1d). In unperturbed trials, the cursor was displayed directly over the
261 occluded robot handle. In randomly selected trials, the cursor's position was decoupled
262 from the robot handle position such that the cursor indicated a reach endpoint position
263 that was rotated (about the start position) relative to the actual reach endpoint position.
264 This was intended to produce sensory prediction error and trial-by-trial compensatory
265 changes in reach angle opposite the direction of the rotations. The rotations were small
266 relative to the size of the target, such that participants nearly always landed in the
267 target, fulfilling the goal of the task and earning a monetary reward (the cursor feedback
268 was within the target on 95.5% of trials, SD: 2%). Thus, reward and task error were
269 constant between perturbed and unperturbed feedback, and by comparing the two
270 conditions we could isolate the neural correlates of sensory error processing.

271
272 In the reward learning task, no cursor appeared to indicate the position of the hand.
273 Instead, binary feedback represented whether or not participants succeeded in hitting
274 the target (Figure 1c). This allowed us to assess reward-based learning in isolation from
275 sensory error processing, as visual information revealing the position of the hand was
276 not provided. In separate blocks, reward feedback was tailored to produce adaptation
277 towards increasingly clockwise and counterclockwise reach angles. Reward was
278 delivered when the difference between the current reach angle and the median of the
279 previous 10 reach angles was in the direction of intended learning. We compared the
280 neural responses to reward and non-reward feedback to assess the neural correlates of
281 reward processing during adaptation.

282 283 ***Apparatus/Behavioral Task***

284
285 Participants produced reaching movements with their right arm while holding the handle
286 of a robotic arm (InMotion2; Interactive Motion Technologies; figure 1). Position of the
287 robot handle was sampled at 600 Hz. A semi-silvered mirror obscured vision of the arm
288 and displayed visual information related to the task. An air sled supported each
289 participant's right arm. Participants reached towards a white circular target 14 cm away
290 from a circular start position in front of their chest. The start position turned from red to
291 green to cue the onset of each reach once the handle had remained inside it
292 continuously for 750 ms. Participants were instructed that they must wait for the cue to
293 begin each reach but that it was not necessary to react quickly upon seeing the cue.
294 Participants were instructed to make forward reaches and to stop their hand within the
295 target. An arc-shaped cursor indicated reach extent throughout each movement without
296 revealing reach angle. In only the first five baseline trials of each block, an additional
297 circular cursor continuously indicated the position of the hand throughout the reach. A
298 viscous force field assisted participants in braking their hand when the reach extent was
299 14 cm. The robot ended each movement by fixing the handle position when the hand
300 velocity decreased below 0.03 m/s. The hand was fixed in place for 700 ms, during
301 which time visual feedback of reach angle was provided. Feedback indicated either
302 reach end point position, a binary reward outcome, or feedback of movement speed
303 (see below). Visual feedback was then removed, and the robot guided the hand back to

304 the start position. Reach end point was defined as the position at which the reach path
305 intersected the perimeter of a circle (14-cm radius) centered at the start position. Reach
306 angle was calculated as the angle between vectors defined by reach end point and the
307 center of the target, each relative to the start position, such that reaching straight ahead
308 corresponds to 0° and counterclockwise reach angles are positive.

309
310 Feedback about reach angle was provided either in the form of end-point position
311 feedback or binary reward feedback. The type of feedback, as well as various feedback
312 manipulations, varied according to the assigned experimental block type (see Reward
313 Learning Task and Visuomotor Rotation Task). Participants were told that they would
314 earn additional monetary compensation for reaches that ended within the target, up to a
315 maximum of \$10 CAD. Movement duration was defined as the time elapsed between
316 the hand leaving the start position and the moment hand velocity dropped below 0.03
317 m/s. If movement duration was >700 ms or <450 ms, no feedback pertaining to
318 movement angle was provided. Instead, a gray arc behind the target turned blue or
319 yellow to indicate that the reach was too slow or too fast, respectively. Participants were
320 informed that movements with an incorrect speed would be repeated but would not
321 otherwise affect the experiment. To minimize the impact of eyeblink-related EEG
322 artifacts, participants were asked to fixate their gaze on a black circular target in the
323 center of the reach target and to refrain from blinking throughout each arm movement
324 and subsequent presentation of feedback.

325
326 *Practice block:* Each participant first completed a block of practice trials that continued
327 until they achieved 50 movements within the desired range of movement duration.
328 Continuous position feedback was provided during the first 5 trials, and only end-point
329 position feedback was provided for the following 10 trials. Subsequently, no position
330 feedback was provided outside the start position.

331
332 *Reward Learning task:* Binary reward feedback was provided to induce adaptation of
333 reach angle (figure 1c). Each session included two blocks in the reward learning
334 condition. The direction of intended learning was clockwise in one block and
335 counterclockwise in the other. Each block continued until the participant completed 125
336 reaches with acceptable movement duration. Participants reached toward a circular
337 target 1.2 cm in diameter. The first 11 reaches were baseline trials during which
338 continuous position feedback was provided during the first 5 trials, followed by 6 trials
339 with only end-point cursor feedback. After these baseline trials no cursor feedback was
340 provided, and binary reward feedback was instead provided at the end of the
341 movement. Target hits and misses were indicated by the target turning green and red,
342 respectively. Unbeknownst to participants, reward feedback did not necessarily
343 correspond to the visual target. Instead, reward was delivered if the difference between
344 the current reach angle and the median angle of the previous 10 reaches was in the
345 direction of intended learning. When the running median was at least 6° away from zero
346 in the direction of intended learning, reward was delivered at a fixed probability of 50%.
347 This was intended to minimize conscious awareness of the manipulation by limiting
348 adaptation to 6°. Reward was never delivered when the absolute value of the reach

349 angle was greater than 10° , for the same reason. We employed this adaptive, closed-
350 loop reward schedule so that the overall frequency of reward was controlled.
351 *Visuomotor rotation task:* End-point feedback was rotated relative to the actual reach
352 angle to induce sensory error-based adaptation (figure 1d). Each session included two
353 blocks in the VMR condition. Each block continued until participants completed 124
354 reaches within acceptable movement duration limits. Participants reached toward a
355 circular target 3.5 cm in diameter. Participants first performed baseline reaches during
356 which cursor feedback reflected veridical reach angle continuously for the first 5 trials
357 and only at movement end point for the subsequent 5 trials. After the baseline reaches
358 the adaptation portion of each block began, unannounced to participants. During the
359 adaptation trials, end-point position feedback was provided indicating a reach angle that
360 was rotated relative to the true reach angle. There were 114 total adaptation trials (38
361 with 0° rotation, and 19 each with $\pm 2^\circ$ and $\pm 4^\circ$ rotations). Participants were instructed
362 that end-point feedback within the target would earn them bonus compensation, but no
363 explicit reward feedback was provided.

364

365 **EEG data acquisition**

366

367 EEG data were acquired from 16 cap-mounted electrodes with an active electrode
368 system (g.GAMMA; g.tec Medical Engineering) and amplifier (g.USBamp; g.tec Medical
369 Engineering). We recorded from electrodes placed according to the 10-20 System at
370 sites Fp1, Fp2, F3, F4, F7, F8, FT9, FT10, FCz, Cz, C3, C4, CPz, CP3, CP4, and Pz
371 referenced to an electrode placed on participants' left earlobe. Impedances were
372 maintained below 5 k Ω . Data were sampled at 4,800 Hz and filtered online with band-
373 pass (0.1–1,000 Hz) and notch (60 Hz) filters. A photodiode attached to the display
374 monitor was used to synchronize recordings to stimulus onset.

375

376 **Behavioral data analysis**

377

378 *Reward learning task.* As in our previous work using a similar task, we computed
379 learning scores in each drug condition by subtracting the average reach angle in the
380 clockwise condition from the average reach angle in the counterclockwise condition
381 (Palidis et al., 2019). As such, positive scores indicate learning. We excluded baseline
382 trials and trials that did not meet the movement duration criteria, as no feedback related
383 to reach angle was provided on these trials. Each block continued until 114 trials after
384 the baseline period met the movement duration criteria, so equal numbers of trials were
385 analyzed for each participant. We tested for the presence of learning by submitting
386 learning scores to 1-sample T-Tests against zero, and we compared learning scores in
387 the placebo and levodopa conditions using paired T-Tests.

388

389 We also analyzed trial-by-trial variability in reach angle in response to reinforcement
390 feedback using an approach similar to Pekny et al. (2015). First, we calculated trial-by-
391 trial changes in reach angle as in Eq. 1:

392

393

394

395 $\Delta\theta_i = \theta_{i+1} - \theta_i$ (1)

396
397 We then multiplied $\Delta\theta_i$ by -1 for trials in the clockwise learning condition, so that positive
398 values for $\Delta\theta_i$ corresponded to changes in reach angle in the direction of intended
399 learning, and any biases in $\Delta\theta$ related to the direction of intended learning would have
400 the same sign in the CW and CCW learning conditions. Next, we conditioned $\Delta\theta_i$ on the
401 reinforcement outcome of trial i and the drug condition to obtain trial-by-trial changes in
402 reach angle following reward and non-reward after both placebo and levodopa
403 administration. Next, we quantified trial by trial variability in each condition as the natural
404 logarithm of the sample variance of $\Delta\theta_i$. Our dependent variable is an estimate of
405 variance. This estimate of variance itself has variance due to sampling. For a normal
406 distribution, the variance of a sample variance is proportional to the square of the true
407 population variance. A log transformation is appropriate for linear modeling when the
408 variance of the dependent measure is proportional to the square of its expectation
409 (Montgomery et al., 2021).

410
411 We then performed 2x2 repeated measures ANOVA on $\text{Log}(\text{var}(\Delta\theta_i))$. The factors were
412 drug (levels: placebo, levodopa), and reward outcome on trial i (levels: non-reward,
413 reward).

414
415 *Visuomotor rotation task.* To quantify trial-by-trial learning we first calculated the change
416 in reach angle between successive trials, as in *Eq. 1*. We then performed a linear
417 regression on $\Delta\theta_i$ with the rotation imposed on trial i as the predictor variable. The
418 rotation was 0° , $\pm 2^\circ$, or $\pm 4^\circ$. This regression was performed on an individual participant
419 basis, separately for placebo and levodopa conditions. We excluded trials that did not
420 meet the duration criteria as no visual feedback was provided on these trials. We took
421 the resulting slope estimates multiplied by -1 as a metric of learning rate, as it reflects
422 the portion of visual errors that participants corrected with a trial-by-trial adaptive
423 process. We tested for the presence of adaptation in each condition by submitting
424 learning rates to 1-sample t-tests against zero. We tested for an effect of levodopa vs
425 placebo on learning rates using a paired t-test.

426 427 **EEG preprocessing**

428
429 EEG data were resampled to 480 Hz and filtered off-line between 0.1 and 35 Hz with a
430 second-order Butterworth filter. Continuous data were segmented into 2-s epochs time-
431 locked to feedback stimulus onset at 0 ms (time range: -500 to +1,500 ms). Epochs
432 flagged for containing artifacts as well as any channels with bad recordings were
433 removed after visual inspection. One participant was excluded entirely from the EEG
434 analysis due to excessive muscle artifacts. Subsequently, extended infomax
435 independent component analysis was performed on each participant's data (Delorme &
436 Makeig, 2004). Components reflecting eye movements and blink artifacts were
437 identified by visual inspection and subtracted by projection of the remaining components
438 back to the voltage time series.

439
440

441 **EEG data analysis**

442
443 After artifact removal, we computed ERPs by trial averaging EEG time series epochs for
444 various feedback conditions described in the sections below. ERPs were computed on
445 an individual participant basis separately for recordings from channels FCz and Pz. We
446 selected FCz and Pz a priori because these electrodes typically correspond to the
447 peaks of the scalp distributions for the feedback related negativity/reward positivity and
448 the P300 ERP components, respectively. We found this to be true in a previous
449 experiment using a very similar paradigm (Palidis et al., 2019). All ERPs were baseline
450 corrected by subtracting the average voltage in the 75-ms period immediately following
451 stimulus onset. We used a baseline period following stimulus onset because stimuli
452 were presented immediately upon movement termination and the period before stimulus
453 presentation was more likely to be affected by movement related artifacts. Trials in
454 which reaches did not meet the movement duration criteria were excluded, as feedback
455 relevant to reach adaptation was not provided on these trials. Finally, ERPs were low-
456 pass filtered with a cutoff frequency of 30 Hz.

457
458 We computed ERPs separately following administration of placebo and levodopa. In the
459 reward learning task, we computed ERPs separately for feedback indicating non-reward
460 (placebo: 107.2 ± 9.7 trials, levodopa: 104.0 ± 8.3 trials) and feedback indicating reward
461 (placebo: 118.4 ± 9.6 trials, levodopa: 118.0 ± 8.1 trials). In the visuomotor rotation task,
462 we computed ERPs separately for veridical endpoint feedback (placebo: 72.6 ± 3.5
463 trials, levodopa: 72.9 ± 3.1 trials), $\pm 2^\circ$ rotated feedback (placebo: 70.8 ± 5.2 trials,
464 levodopa: 72.1 ± 3.8 trials), and $\pm 4^\circ$ rotated feedback (placebo: 64.5 ± 4.7 trials,
465 levodopa: 66.3 ± 4.1 trials). We excluded trials in which the cursor did not land within
466 the target.

467
468 We selected time windows of interest for ERP analysis using independent data from a
469 previous experiment with very similar procedures (Palidis et al., 2019). We analyzed the
470 amplitudes of FRN/RP and P300 components within 50 ms time windows centered
471 around the latencies of the FRN/RP and P300 peaks observed in our previous study.
472 The FRN/RP peak was taken as the maximum value of the difference between ERPs
473 elicited by reward and non-reward feedback recorded from electrode FCz (latency:
474 292ms). For completeness, we used the same time window to test for FRN/RP effects
475 in the visuomotor rotation task of the current study although we did not observe an
476 FRN/RP component in our previous visuomotor rotation task. The P300 peak latencies
477 were determined separately for reward and non-reward feedback as the times of
478 maximal amplitude of ERPs recorded from electrode Pz (reward: 319ms, non-reward:
479 371ms). The peak latencies selected for the FRN/RP and P300 components in the
480 reward learning task corresponded very closely to the peaks observed in the current
481 data. However, the P300 peak in the visuomotor rotation task of the current study was
482 earlier than that in our previous experiment. This difference in latency may be due to
483 changes in the nature of the feedback. Thus, we determined the latency of the P300
484 peak in the visuomotor rotation task of the current study using a data-driven method that
485 does not bias comparisons between conditions (Brooks et al., 2017). We aggregated all
486 trials across conditions and participants and computed a trial averaged ERP using

487 recordings from electrode Pz. The P300 peak was determined as the maximal
488 amplitude of this averaged waveform (latency: 317ms). This method is only suitable for
489 comparing waveforms of different amplitude but similar morphology across conditions,
490 and thus could not be applied to the ERPs in the reward learning task (Brooks et al.,
491 2017).

492
493 We tested for effects of feedback manipulations on FRN/RP components using the
494 average amplitude of ERPs recorded from electrode FCz within the FRN/RP time
495 window. We tested for effects on P300 ERP components using average amplitude of
496 ERPs recorded from electrode Pz within the P300 time window corresponding to a
497 given condition. For the reward learning task, we used 2x2 repeated measures
498 ANOVAs with factors drug (levels: placebo, levodopa) and reinforcement outcome
499 (levels: reward, non-reward). For the visuomotor rotation task, we used 2x3 repeated
500 measures ANOVAs with factors drug (levels: placebo, Levodopa), and rotation (levels:
501 0°, ±2°, ±4°).

502 503 **Experiment 2**

504 505 ***Participants***

506
507 A total of 38 participants were included in experiment 2 (Table 2). All participants were
508 screened for neurological and psychiatric illness, history of drug or alcohol abuse, and
509 contraindications for levodopa. Participants provided written informed consent to
510 experimental procedures approved by the Research Ethics Board at Western
511 University.

512 513 ***Procedure***

514
515 *Drug administration:* Participants were administered either levodopa or placebo in a
516 randomized double-blind design. A capsule was ingested that contained 100 mg of
517 levodopa (L-3,4-dihydroxyphenylalanine) and 25 mg of carbidopa or an equal volume of
518 placebo. The experimental tasks began 45 minutes after ingestion of the capsule to
519 coincide with peak plasma levels of levodopa. We measured subjective alertness using
520 the Bond-Lader visual analog scale (Bond & Lader, 1974) as well as heart rate and
521 blood pressure immediately prior to ingesting the capsule and again at the end of each
522 session.

523
524 *Force field adaptation task:* Participants produced reaching movements with their right
525 arm while holding the handle of a robotic arm (InMotion2; Interactive Motion
526 Technologies). The position of the robot handle was sampled at 600 Hz. A semi-silvered
527 mirror obscured vision of the arm and displayed visual information related to the task.
528 An air sled supported each participant's right arm.

529
530 On each trial, participants reached from a central home position (blue circle 20 mm in
531 diameter) to one of 8 circular targets (24 mm in diameter) arranged around the home
532 position at a distance of 10 cm. The target angles were 0°, 45°, 90°, 135°, 180°, 225°, 270°.

533 270°, and 315°. A 5-mm pink circular cursor represented the position of the robot
534 handle. When the cursor reached the target on each trial, the target either turned blue to
535 indicate that the movement duration was satisfactory (375 ± 100 ms), green to indicate
536 that the movement was too slow, or red to indicate that the movement was too fast. The
537 subject moved the robot handle back to the home position at the end of each reach.
538

539 In null field blocks, the robot motors did not apply any external forces to the hand. In
540 force field blocks, the robot applied forces to the hand that were perpendicular to the
541 direction of movement and proportional to the velocity of the hand (eq. 2). The direction
542 of the force field was either clockwise or counterclockwise, in separate blocks.
543

$$544 \begin{bmatrix} F_x \\ F_y \end{bmatrix} = b \begin{bmatrix} 0 & d \\ -d & 0 \end{bmatrix} \begin{bmatrix} v_x \\ v_y \end{bmatrix} \quad (2)$$

545
546 x and y correspond to the lateral and sagittal directions. F_x and F_y describe the forces
547 applied to the hand, v_x and v_y describe the velocity of the hand, b is the field constant,
548 and d corresponds to the direction ($d = 1$ for a clockwise force field (CWFF), -1 for a
549 counterclockwise force field (CCWFF) or 0 for a null field (NF)).
550

551 All participants completed five blocks of 96 trials. Each block consisted of 12 reaches to
552 each of the 8 targets presented in random order. The five blocks occurred in the
553 following order: NFa (null field), FF1a (CWFF), NFb (null field), FF1b (CWFF), FF2
554 (CCWFF). Trials 6, 24, 35, 50, 71, and 91 of each block were “catch trials”, during which
555 reaches occurred in a null field. When the force field is suddenly removed in catch trials,
556 errors occur in the opposite direction of the force field. A reduction in reach error during
557 force field trials may reflect either adaptation to the force field, stiffening of the arm, or
558 changes in feedback corrections. The magnitude of errors opposite the force field in
559 catch trials is thought to better capture adaptation of feedforward control. Similar to
560 catch trials, we expected after-effects at the beginning of NFa in the form of
561 counterclockwise reach errors after the sudden removal of the clockwise force field in
562 FF1a.
563

564 **Data analysis**

565
566 Robot handle positional data were low-pass filtered with a 40 Hz cutoff frequency and
567 differentiated to yield instantaneous velocity and acceleration. On each trial, movement
568 onset and end of movement were defined according to a velocity threshold set at 5% of
569 the maximum tangential velocity of the robot endpoint. Our behavioral measure of
570 interest was the lateral deviation of the hand at the time of peak tangential velocity.
571 Perpendicular deviation (PD) was calculated relative to a line drawn from the position of
572 movement onset in the direction of the target angle (either 0°, 45°, 90°, 135°, 180°,
573 225°, 270°, or 315°). PD was calculated for each trial as the perpendicular distance
574 between the position of the hand at peak velocity and this line, with positive PD
575 corresponding to clockwise deviations. For non-catch trials, PD was averaged across
576 trials within 12 bins of 8 trials each. We analyzed effects related to adaptation

577 separately for an early and late period of each block. The early period consisted of the
578 first 5 bins (trials 1-40, catch trials: 6,24,35) and the late period consisted of the
579 remaining 7 bins (trials 41-96, catch trials: 50,71,91). Baseline PD was computed as the
580 average PD in the late period of NFa. We computed metrics for adaptation, savings,
581 after-effects, and learning with interference separately for the early and late periods,
582 and separately for catch trials and non-catch trials. All metrics were computed so that
583 positive values corresponded to the effects of interest, and values of zero correspond to
584 no effect. We tested for adaptation, savings, after-effects, and learning with interference
585 using 1-sample t-tests against zero. We tested for differences between the placebo and
586 levodopa groups using paired t-tests.

587 *Non-catch trials:* Adaptation metrics were computed to capture reductions in error
588 during FF1a relative to the initial errors caused by the onset of the force field. Our
589 measure of early adaptation was the average PD in the first bin of FF1a minus the
590 average PD across subsequent bins within the early period of FF1a (bins 2-5). Our
591 measure of late adaptation was the average PD in the first bin of FF1a minus the
592 average PD across bins in the late period of FF1a (bins 6-12). Savings metrics were
593 computed to measure reductions in errors during the second exposure to FF1
594 compared to the first. Savings was measured as the difference in PD between FF1a
595 and FF1b (FF1a – FF1b), separately for PD averaged across bins within the early and
596 late periods. Adaptation to FF1a caused after-effects in the form of errors upon its
597 sudden removal at the onset of NFb. After-effects were measured as the difference
598 between baseline PD and the PD in NFb (baseline – NFb), separately for PD averaged
599 across bins in the early and late periods of NFb. We expected large initial errors at the
600 onset of FF2 due to a combination of after-effects from the removal of FF1b and the
601 introduction of a novel force field. Previous adaptation to FF1b was also expected to
602 cause anterograde interference during adaptation to FF2 as the force fields were
603 opposite. Metrics for adaptation with interference were computed to capture reductions
604 in errors during FF2 relative to the initial errors caused by the onset of the force field.
605 Early adaptation with interference was measured by subtracting the average PD from
606 the first bin of FF2 from the average PD across subsequent bins within the early period
607 of FF2 (bins 2-5). Late adaptation with interference was measured by subtracting the
608 average PD in the first bin of FF2 from the average PD across subsequent bins in the
609 late period of FF2 (bins 6-12).

610 *Catch trials:* When a force field is suddenly removed during catch trials, adaptation to
611 the force field is reflected in errors opposite the direction of the force field. Adaptation
612 effects were computed as the baseline PD minus the PD in FF1a averaged across
613 catch trials, separately for catch trials in the early and late period. Improved adaptation
614 due to savings was expected to cause larger errors in catch trial during FF1b compared
615 to FF1a. Savings was computed as the PD in FF1a minus the PD in FF1b, averaged
616 across catch trials separately for the early and late periods. Learning effects with
617 interference were computed using data from FF2. There was no suitable baseline PD to
618 analyze learning in this block. Instead, the PD of the first catch trial was subtracted from
619 the PD of each of the later catch trials, separately for catch trials in the early and late
620 periods. This captures changes in catch trial PD opposite the direction of FF2 due to
621 adaptation.

622

623 **Statistics**

624

625 Statistical tests were implemented using JASP v0.14.1. We compared sample means
626 using 1 sample T-Tests, paired sample T-Tests, or independent sample T-Tests. These
627 comparisons allowed us to compute one-tailed Bayes factors representing
628 $p(\text{data}|H_+) / p(\text{data}|H_0)$, where H_0 represents the null hypothesis corresponding to the
629 standard t -distribution for an effect size of 0, and H_+ represents the alternative
630 hypothesis corresponding to a t -distribution constructed using a one-tailed prior
631 distribution of effect sizes. The use of 1-tailed priors is recommended in the case of
632 directional hypotheses to provide “a fairer balance between the ability to provide
633 evidence for H_0 and H_1 ” (Keysers et al., 2020). We used the default effect size priors
634 implemented in JASP (Cauchy scale 0.707). These priors are generally appropriate for
635 effect sizes typical of neuroscience research, and the use of default priors is
636 recommended for standardized and objective analysis (Keysers et al., 2020; Rouder et
637 al., 2012; Wetzels et al., 2011). Bayesian estimates of effect size are reported as
638 median posterior Cohen’s d with 95% credibility interval using 2-tailed priors for H_1 to
639 avoid biasing the estimate in the expected direction. We also report T-statistics, p-
640 values, and 95% confidence intervals generated using 2-tailed frequentist T-Tests. For
641 factorial analyses, we conducted frequentist and Bayesian repeated measures ANOVAs
642 using JASP with default priors. Bayes factors were computed for the inclusion of each
643 effect as the ratio of the data likelihood under the model containing that effect vs
644 equivalent models stripped of that effect. Bayes factors >3 and >10 were taken as
645 moderate and strong evidence in favor of the alternative hypothesis, respectively. Bayes
646 factors $<1/3$ and $<1/10$ were taken as moderate and strong evidence in favor of the null
647 hypothesis, respectively. Bayes factors between $1/3$ and 3 were taken as inconclusive
648 evidence (Keysers et al., 2020).

649

650 Directional priors used for alternative hypotheses specified our predictions that learning
651 metrics would be greater than zero (Reward learning score, VMR learning rate, force
652 field adaptation, savings, after-effects, and adaptation with interference). In comparing
653 placebo and levodopa conditions, our alternative hypotheses specified that learning
654 metrics would be lower in levodopa conditions than placebo conditions, in accordance
655 with the “dopamine overdose” hypothesis. The only exception was that we predicted
656 adaptation with interference would be increased by levodopa. If anterograde
657 interference is caused by dopaminergic reinforcement learning, then the “dopamine
658 overdose” effect should reduce interference and facilitate adaptation. All other Bayes
659 factors are computed with 2-tailed priors, as they were conducted without directional a
660 priori hypotheses (control measures, etc.).

661

662 **Results**

663

664 **Experiment 1**

665

666 *Control measures:* Participants’ judgments at the end of the second session as to
667 whether they received placebo or drug were correct at near chance level (47.62%).

668 Table 1 shows the values for heart rate, blood pressure, and alertness recorded at the
669 beginning and end of each experimental session for both the placebo and levodopa
670 conditions. We computed the percent change in heart rate and blood pressure recorded
671 at the beginning and end of each session. There were no reliable differences between
672 the levodopa and placebo conditions in the percent change of heart rate ($t(18) = 0.70$,
673 $p=0.49$, 95%CI for difference = [-0.03 0.07], BF = 0.30, posterior δ : median = 0.139,
674 95%CI = [-0.278 0.565]), systolic blood pressure ($t(18) = -0.39$, $p=0.70$, 95%CI for
675 difference = [-0.06 0.04], BF = 0.25, posterior δ : median = -0.077, 95%CI = [-0.498
676 0.338]), or diastolic blood pressure ($t(18) = -0.88$, $p=0.39$, 95%CI for difference = [-0.07
677 0.03], BF = 0.33, posterior δ : median = -0.173, 95%CI = [-0.603 0.245]). We did observe
678 a significant difference between levodopa and placebo in the percent change of
679 alertness ($t(20) = 2.46$, $p=0.023$, 95%CI for difference = [0.02 0.19], BF = 2.53, posterior
680 δ : median = 0.477, 95%CI = [0.044 0.930]). However, this effect was likely due to
681 chance as alertness was only different between the two drug conditions at the time point
682 pre-administration of the capsule ($t(20) = 2.18$, $p=0.042$), but not post-administration
683 ($t(20) = -0.068$, $p=0.95$). We also tested for effects of levodopa on the median response
684 time (the latency between the go cue and the robot handle leaving the home position),
685 and the median movement time (table 1). We observed no reliable differences in
686 response time between the placebo and levodopa conditions in either the reward
687 learning task ($t(20)=0.72$, $p=0.48$, 95%CI for difference = [-37.49 77.34], BF = 0.29,
688 posterior δ : median = 0.137, 95%CI = [-0.261 0.545]), or the VMR task ($t(20)=0.62$,
689 $p=0.54$, 95%CI for difference = [-33.91 62.56], BF = 0.27, posterior δ : median = 0.118,
690 95%CI = [-0.280 0.523]). We also observed no reliable difference in movement time
691 between the placebo and levodopa conditions in either the reward learning task ($t(20)=-$
692 0.11, $p=0.91$, 95%CI for difference = [-20.75 18.69], BF = 0.23, posterior δ : median = -
693 0.021, 95%CI = [-0.420 0.377]), or the VMR task ($t(20)=-0.21$, $p=0.84$, 95%CI for
694 difference = [-16.21 13.27], BF = 0.23, posterior δ : median = -0.039, 95%CI = [-0.44
695 0.358]).

696 **Behavioral results**

697 *Reward learning task.* Behavioral data from the reward learning task are shown in
698 Figure 2. Learning scores were reliably greater than zero in both the placebo condition
699 (mean = 6.03, SD = 3.58, $t(20) = 7.72$, $p = 2.02e-7$, 95%CI = [4.40 7.66], BF = 1.56e5,
700 posterior δ : median = 1.58 95%CI = [0.92 2.28]), and the levodopa condition (mean =
701 6.93, SD = 3.86, $t(20) = 8.23$, $p = 7.49e-8$, 95%CI = [5.17 8.69], BF = 3.9e5, posterior δ :
702 median = 1.69, 95%CI = [1.00 2.41]) conditions. Learning scores were slightly higher in
703 the levodopa condition, though this difference was not statistically reliable. This result
704 provided strong evidence against our hypothesis of reduced learning in the levodopa
705 group ($t(20) = -1.58$, $p = 0.13$, 95%CI for difference = [-2.09 0.29], BF = 0.10, posterior
706 δ : median = -0.30, 95%CI = [-0.73 0.11]). We observed similar evidence against the
707 hypothesized effect of levodopa when learning scores were computed using only the
708 final 20 trials in each block ($t(20) = -1.60$, $p = 0.13$, 95%CI for difference = [-3.05 0.40],
709 BF = 0.10, posterior δ : median = -0.31, 95%CI = [-0.73 0.10]).

710
711
712

713 The variability of trial-by-trial changes in reach angle following reward and non-reward
714 outcomes is shown in Figure 3. We found a reliable main effect of reinforcement
715 outcome on the log transformed variance of trial-by-trial changes in reach angle ($F(1,20)$
716 $= 74.84$, $p = 3.41e-8$, $\eta_p^2 = 0.79$, $BF = 3.02e14$). This indicates an increase in trial-by-trial
717 variance of reach angle following non-reward outcomes relative to reward. We found
718 moderate evidence against effects of drug condition ($F(1,20) = 0.0072$, $p = 0.93$, $\eta_p^2 =$
719 $3.86e-4$, $BF = 0.22$) and reward by drug interaction ($F(1,20) = 0.0478$, $p =$
720 0.829 , $\eta_p^2 = 2.38e-3$, $BF = 0.30$).

721
722 *Visuomotor rotation task.* Mean trial-by-trial changes in reach angle after the different
723 feedback rotations are shown in Figure 4. Learning rates were reliably greater than zero
724 following administration of both placebo (mean: 0.313, SD: 0.133, $t(20) = 10.77$, $p =$
725 $8.93e-10$, 95%CI = [0.25 0.37], $BF = 2.4e7$, posterior δ : median = 2.22, 95%CI = [1.40
726 3.10]) and levodopa (mean: 0.294, SD: 0.102, $t(20) = 13.18$, $p = 2.54e-11$, 95%CI =
727 [0.25 0.34], $BF = 6.75e8$). Learning rates were not reliably different in the two
728 conditions ($t(20) = 0.703$, $p = 0.491$, 95%CI for difference = [-0.04 0.07], $BF = 0.42$,
729 posterior δ : median = 0.134, 95%CI = [-0.265 0.540]).

730

731

732 **Event-related potential results**

733

734 *Reward learning task.*

735

736 Feedback-related negativity/Reward positivity: Event-related potentials (ERPs) elicited
737 by reinforcement feedback at electrode FCz are shown in Figure 5a. We analyzed the
738 FRN/RP by submitting the average ERP amplitude at electrode FCz between 267-
739 317ms to frequentist and bayesian repeated measures ANOVAs (figure 5b). We found a
740 reliable main effect of reward outcome on FRN/RP amplitude ($F(1,19) = 42.25$, $p =$
741 $3.16e-6$, $\eta_p^2 = 0.69$, $BF = 8.89e8$). We observed moderate evidence both against an effect
742 of drug ($F(1,19) = 0.13$, $p = 0.73$, $\eta_p^2 = 6.56e-3$, $BF = 0.24$) and a reward by drug
743 interaction ($F(1,19) = 0.2$, $p = 0.66$, $\eta_p^2 = 0.01$, $BF = 0.30$) on FRN/RP amplitude.

744

745 P300: ERPs elicited by reinforcement feedback at electrode Pz are shown in Figure 5c.
746 We analyzed the P300 by submitting the average ERP amplitudes at electrode Pz
747 during the P300 time windows (Reward: 294-344ms, Non-reward: 346-396ms) to
748 frequentist and bayesian repeated measures ANOVAs (figure 5d). We found a reliable
749 main effect of reward outcome on P300 amplitude ($F(1,19) = 35.83$, $p = 9.26e-6$,
750 $\eta_p^2 = 0.65$, $BF = 3.5e5$). We observed moderate evidence both against an effect of drug
751 ($F(1,19) = 0.20$, $p = 0.66$, $\eta_p^2 = 0.01$, $BF = 0.26$) and against a reward by drug interaction
752 ($F(1,19) = 0.13$, $p = 0.73$, $\eta_p^2 = 6.56e-3$, $BF = 0.29$) on P300 amplitudes.

753

754 *Visuomotor rotation task.*

755

756 Feedback-related negativity/Reward positivity: ERPs elicited by endpoint cursor
757 feedback at electrode FCz are shown in Figure 6a. We analyzed the FRN/RP by

758 submitting the average ERP amplitude at electrode FCz between 267-317ms to
759 repeated measures ANOVAs (figure 6b). We did not find reliable main effects of drug
760 ($F(1,19) = 1.37$, $p = 0.26$, $\eta_p^2=0.07$), or feedback rotation ($F(2,38) = 0.1$, $p = 0.86$
761 (Greenhouse-Geisser corrected), $\eta_p^2= 5.12e-3$). We did observe a reliable drug by
762 rotation interaction effect ($F(2,38) = 4.75$, $p = 0.02$ (Greenhouse-Geisser corrected), $\eta_p^2=$
763 0.2). Simple main effects did not show reliable main effects of rotation in either the
764 placebo ($F(2,38) = 2.17$, $p=0.13$) or levodopa ($F(2,38) = 2.06$, $p=0.14$) conditions on
765 FRN/RP amplitudes.

766
767 P300: ERPs elicited by endpoint cursor feedback at electrode Pz are shown in Figure
768 6c. We analyzed the P300 by submitting the average ERP amplitude at electrode Pz
769 between 292-342 ms to repeated measures ANOVAs (figure 6d). We did not find
770 reliable main effects of drug ($F(1,19) = 0.43$, $p = 0.52$, $\eta_p^2=0.02$), or feedback rotation
771 ($F(2,38) = 1.31$, $p = 0.28$ (Greenhouse-Geisser corrected), $\eta_p^2= 0.06$). We did observe a
772 reliable drug*rotation interaction effect ($F(2,38) = 7.46$, $p = 2.24e-3$ (Greenhouse-
773 Geisser corrected), $\eta_p^2= 0.28$). Simple main effects revealed a reliable main effect of
774 rotation in the placebo ($F(2,38) = 5.72$, $p=6.72e-3$) but not the levodopa ($F(2,38) = 0.51$,
775 $p=0.60$) condition on P300 amplitude.

776 777 **Experiment 2**

778
779 *Control measures:* Participants' judgments as to whether they received placebo or drug
780 was near chance level (52.63%) and only 13.16% of participants responded that they
781 thought they had received the drug. The values for heart rate, blood pressure, and
782 alertness are reported in Table 2 for both the placebo and levodopa groups at the
783 beginning and end of each experimental session. There were no reliable differences
784 between the levodopa and placebo conditions in the percent change of heart rate ($t(36)$
785 $= -1.09$, $p=0.282$, 95%CI for difference = [-0.10 0.03], BF = 0.5, posterior δ : median = -
786 0.273, 95%CI = [-0.875 0.284]), diastolic blood pressure ($t(36) = 1.37$, $p=0.18$, 95%CI
787 for difference = [-0.02 0.11], BF = 0.65, posterior δ : median = 0.346, 95%CI = [-0.218
788 0.960]), systolic blood pressure ($t(36) = 1.37$, $p=0.18$, 95%CI for difference = [-.02 0.09],
789 BF = 0.65, posterior δ : median = 0.346, 95%CI = [-0.218 0.960]), or alertness ($t(36) = -$
790 0.88, $p=0.39$, 95%CI for difference = [-0.95 0.38], BF = 0.43, posterior δ : median = -
791 0.218, 95%CI = [-0.810 0.337]). There was also no reliable difference between peak
792 movement velocity between the levodopa and placebo groups ($t(36) = -0.09$, $p=0.93$,
793 95%CI for difference = [-0.01 9.94e-3], BF = 0.32, posterior δ : median = -0.021, 95%CI
794 = [-0.585 0.539]).

795 796 **Force field adaptation results**

797
798 In each trial, we measured the perpendicular deviation (PD) of the reach trajectory at
799 peak tangential velocity. PD data from throughout each force field and null field block,
800 excluding catch trials, are shown in Figure 7. PD data from catch trials are shown in
801 Figure 8. We computed contrasts to test for adaptation, savings, after-effects, and
802 learning with interference in both the early (bins 1-5) and late (bins 6-12) periods
803 following perturbation onset (Figure 9). We tested whether these effects are different

804 from zero using 1-sample T-Tests for both the levodopa and placebo groups. We tested
805 for differences between the levodopa and placebo groups using independent sample T-
806 Tests. Detailed statistical results are shown in Table 3.

807

808 **Adaptation:**

809

810 *Non-catch trials:* Early adaptation was greater than zero in both the placebo ($p=3.62e-9$,
811 $BF=6.36e+6$) and levodopa conditions ($p=6.61e-8$, $BF=432848$). We also observed
812 reliable late adaptation for both the placebo ($p=2.48e-10$, $BF=7.72e+7$) and levodopa
813 ($p=4.71e-9$, $BF=4.99e+6$) conditions. We did not observe a reliable difference between
814 drug conditions for either early ($p=0.83$, $BF=0.37$) or late ($p=0.57$, $BF=0.22$) adaptation.

815

816 *Catch trials:* Early adaptation was greater than zero in both the placebo ($p=4.82e-8$,
817 $BF=574167$) and levodopa ($p=3.62e-8$, $BF=755029$) conditions. We observed reliable
818 late adaptation in both the placebo ($p=2.92e-7$, $BF=110522$) and levodopa ($p=2.54e-11$,
819 $BF=6.48e+8$) conditions. There was no reliable difference between drug conditions for
820 either early ($p=0.61$, $BF=0.47$), or late ($p=0.90$, $BF=0.29$) adaptation.

821

822 **Savings:**

823

824 *Non-catch trials:* Our analyses yielded inconclusive evidence in favor of the
825 hypothesized effect of savings for early adaptation for both the placebo ($p=0.14$,
826 $BF=1.23$) and levodopa ($p=0.11$, $BF=1.43$) conditions. In the late period of adaptation,
827 Non-catch trials provided inconclusive evidence against the hypothesized effect of
828 savings following placebo ($p=0.50$, $BF=0.44$), and moderate evidence against the
829 hypothesized effect of savings following levodopa ($p=0.70$, $BF=0.18$). There was
830 moderate evidence against the hypothesis that savings would be reduced by levodopa
831 in early adaptation ($p=0.87$, $BF=0.28$), and inconclusive evidence that savings would be
832 reduced in late adaptation ($p=0.45$, $BF=0.59$).

833

834 *Catch trials:* There was moderate evidence against the hypothesized effects of savings
835 for early adaptation following both placebo ($p=0.72$, $BF=0.33$) and levodopa ($p=0.75$,
836 $BF=0.19$). Evidence for savings in late adaptation was inconclusive following both
837 placebo ($p=0.14$, $BF=1.20$) and levodopa ($p=0.33$, $BF=0.60$). There was inconclusive
838 evidence against the hypothesis that levodopa would reduce savings for both early
839 ($p=0.63$, $BF=0.47$) and late ($p=0.39$, $BF=0.66$) adaptation.

840

841 **After-Effects:**

842

843 *Non-catch trials:* We observed reliable after-effects in the early portion of NFb following
844 adaptation in both the placebo ($p=4.00e-8$, $BF=688519.55$) and levodopa ($p=2.56e-9$,
845 $BF=8.79e+6$) conditions. We also observed reliable after-effects extending to the later
846 period of NFb after both placebo ($p=1.37e-3$, $BF=56.24$) and levodopa ($p=9.66e-4$,
847 $BF=76.15$). We observed no reliable evidence that levodopa impaired after-effects in
848 either the early ($p=0.99$, $BF=0.32$) or late ($p=0.78$, $BF=0.39$) periods.

849

850 **Adaptation with interference:**

851
852 *Non-catch trials:* Early adaptation following exposure to an opposing force field was
853 reliably greater than zero in both the placebo ($p=1.06e-9$, $BF=2.00e+7$) and levodopa
854 ($p=3.42e-6$, $BF=11657.42$) conditions. We also observed reliable late adaptation in both
855 the placebo ($p=5.98e-12$, $BF=2.51e+9$) and levodopa ($p=1.70e-9$, $BF=1.28e+7$)
856 conditions. We observed moderate evidence against the hypothesized effect that
857 levodopa would result in improved adaptation with interference in both the early
858 ($p=0.23$, $BF=0.16$) and late ($p=0.18$, $BF=0.15$) periods.

859
860 *Catch trials:* Early adaptation following exposure to an opposing force field was reliably
861 greater than zero in both the placebo ($p=6.37e-5$, $BF=837.09$) and levodopa ($p=4.84e-6$,
862 $BF=8524.02$) conditions. We also observed reliable late adaptation in both the placebo
863 ($p=4.33e-7$, $BF=77010.30$) and levodopa ($p=4.20e-8$, $BF=657919.38$) conditions. We
864 observed inconclusive evidence against the hypothesis that levodopa would result in
865 improved adaptation with interference in the early period ($p=0.65$, $BF=0.45$), and
866 moderate evidence in the late period ($p=0.77$, $BF=0.26$).

867

868 **Discussion**

869

870 We tested for effects of levodopa, a dopamine precursor, in three different motor
871 adaptation tasks across two experiments. In the first experiment we recorded EEG
872 during a reward-based motor adaptation task and a sensory error-based visuomotor
873 rotation (VMR) adaptation task. In the second experiment, we used a force field
874 adaptation paradigm to test for effects of levodopa on initial adaptation, savings, and
875 anterograde interference. We hypothesized that levodopa would selectively impair
876 neural and behavioral responses to reinforcement feedback in the reward-based
877 learning task as well as savings and interference. However, the only reliable influence of
878 levodopa was in modulating the effect of visuomotor rotation on the P300 event-related
879 potential component.

880

881 *Visuomotor rotation task:* During the VMR task included in experiment 1, a cursor
882 appeared at the endpoint of each reach to represent the position of the hand, and this
883 feedback was perturbed through random rotations. We observed robust trial-by-trial
884 adaptation to these perturbations. We did not find evidence that adaptation was affected
885 by levodopa. This was expected, as trial-by-trial error correction induced by relatively
886 small visuomotor rotations is thought to be driven primarily by sensory error-based
887 learning mechanisms as opposed to dopaminergic reinforcement learning circuits
888 (Diedrichsen et al., 2005; Ito, 2000; Krakauer et al., 2004; Tanaka et al., 2009; Jordan
889 A. Taylor et al., 2010; Wong et al., 2019).

890

891 It has previously been shown that visuomotor rotation increases the amplitude of the
892 P300 ERP component, a centro-parietal ERP deflection peaking approximately 300-
893 400ms following feedback presentation (Aziz et al., 2020; MacLean et al., 2015; Palidis
894 et al., 2019). In the present study, we observed an interaction effect between feedback
895 rotation and drug condition on the P300 amplitude. P300 amplitude increased in

896 response to visuomotor rotations in the placebo condition but not in the levodopa
897 condition. This result replicates previous findings that visuomotor rotations increase the
898 amplitude of P300 responses to feedback, and additionally suggests that this effect is
899 dependent on dopaminergic signaling. The modulation of P300 amplitude by sensory
900 error is clearly not essential for adaptation, as disruption of this effect by levodopa did
901 not correspond with any behavioral changes. Previous findings have also suggested a
902 relationship between dopamine function and the P300 response, however the neural
903 mechanisms and functional significance of the P300 in relation to motor adaptation
904 remain unclear (Chu et al., 2018; Hansenne et al., 1995; Mulert et al., 2006; Noble et
905 al., 1994; Sohn et al., 1998; Stanzione et al., 1990, 1991; Takeshita & Ogura, 1994).
906 Variants of the P300 are elicited by many types of task-relevant stimuli, and have been
907 localized to diffuse cortical areas including parietal, frontal, and motor regions, which
908 have been implicated in processing prediction error (Bledowski et al., 2004; Calhoun et
909 al., 2006; Johnson et al., 2019; Li et al., 2009; Mantini et al., 2009; Polich, 2007;
910 Ragazzoni et al., 2019; Sabeti et al., 2016; Soltani & Knight, 2000). We observed a
911 similar interaction effect between rotation and drug condition in recordings from
912 electrode FCz during the FRN/RP time window. This appeared to be largely attributable
913 to the P300 effect described above, as the time windows were mostly overlapping and
914 the P300 was clearly measured at FCz as well.

915
916 *Reward learning task:* Participants adapted reliably to manipulations of binary
917 reinforcement feedback intended to produce either progressively clockwise or
918 counterclockwise reach angles. However, we found no effects of levodopa on
919 adaptation. One explanation of our findings is that the behavioral and neural processes
920 measured in the current study do not depend on dopaminergic reward learning
921 mechanisms. Another possibility is that the drug manipulation was not sufficiently
922 powerful to disrupt these processes. The former interpretation depends on previous
923 findings that levodopa impairs cognitive forms of reward learning using the same drug
924 administration protocols in similar populations. However, the current study is limited by
925 the lack of a positive control task demonstrating known behavioral effects of levodopa.
926 Quattrocchi et al. (2018) found no effect of levodopa or a dopamine antagonist
927 haloperidol on modulation of sensory error-based learning by additional reinforcement
928 feedback. Holland et al. (2019) found no association between dopamine-related gene
929 polymorphisms on adaptation through binary reinforcement feedback in a task similar to
930 that used in the current study. Together, these findings suggest that reward-based
931 motor adaptation may not rely on dopamine function, or at least that additional
932 mechanisms may compensate for differences in dopamine function.

933
934 The “dopamine overdose” hypothesis states that dopaminergic medications such as
935 levodopa might disrupt learning processes mediated by the ventral striatum by
936 overstimulating dopamine signaling in this brain region. The ventral striatum may
937 specifically mediate stimulus-based reinforcement learning, while action-based
938 reinforcement learning in the current study may be subserved by the dorsal striatum
939 (Rothenhoefer et al., 2017). Furthermore, levodopa may specifically impair learning
940 from unfavorable outcomes as opposed to rewarding outcomes (Cools et al., 2006,
941 2007; Frank et al., 2004; Vo et al., 2018). Non-reward outcomes in the current task may

942 not contribute significantly to learning as they do not instruct the correct response,
943 unlike in binary response tasks.

944
945 Another important distinction is between model-free and model-based reinforcement
946 learning processes (Babayan et al., 2018; Daw et al., 2011; Deserno et al., 2015; Dolan
947 & Dayan, 2013; Doll et al., 2016; Gardner et al., 2018; Gläscher et al., 2010; Russek et
948 al., 2017; Sambrook et al., 2018; Shahar et al., 2019; Sharp et al., 2016). Model-free
949 reinforcement learning is characterized by reinforcement of simple stimulus-response
950 associations that facilitate habitual, reflexive responding. Model-based learning allows
951 for flexible planning according to a mental representation of the task, and can be limited
952 by working memory processes. Levodopa has been shown to impair reward-based
953 learning in healthy controls and people with Parkinson's disease, but to improve model-
954 based learning and related cognitive functions such as working memory, cognitive
955 flexibility, and attention (Beato et al., 2008; R. Cools et al., 2001; Roshan Cools et al.,
956 2003; Cooper et al., 1992; Costa et al., 2003; Kulisevsky, 2000; Lange et al., 1992;
957 Lewis et al., 2005; Marini et al., 2003; Moustafa et al., 2008; Sharp et al., 2016; Torta et
958 al., 2009; Wunderlich et al., 2012). It is possible that "dopamine overdose" by levodopa
959 selectively impairs model-free learning. It may be that reward-based motor adaptation in
960 the current study relies on processes other than model-free learning that are not
961 affected by levodopa. Reward-based motor adaptation tasks similar to that in the
962 current study have been shown to primarily involve strategic aiming that can be
963 influenced by explicit instructions and cognitive load, characteristics that are
964 inconsistent with model-free learning (Codol et al., 2018; Holland et al., 2018).

965
966 We also analyzed the variability of trial-by-trial changes in reach angle as a function of
967 reward outcomes. Reward related modulation of motor variability has been shown to be
968 impaired in medicated Parkinson's disease in a very similar task (Pekny et al., 2015).
969 We hypothesized that this effect may be due to side-effects of dopaminergic medication,
970 and that we would observe similar impairments in healthy participants after levodopa
971 administration. However, we observed no effect of levodopa on reward-related
972 modulation of motor variability. Reward-based modulation of exploratory variance may
973 therefore not depend on the ventral striatum, which is relatively spared in early stage
974 Parkinson's disease and therefore vulnerable to "dopamine overdose" in patients and
975 healthy controls alike. Instead, it may depend on the dorsal striatum, which is more
976 closely related to movement planning and is primarily impacted by early stage
977 Parkinson's disease.

978
979 Reinforcement feedback elicited a very reliable FRN/RP ERP component. Meta
980 analyses have shown that the FRN/RP encodes a quantitative reward prediction error
981 across multiple different tasks (Sambrook & Goslin, 2015; Walsh & Anderson, 2012).
982 Reports have linked the FRN/RP signal to behavioral adjustments in response to
983 feedback (Arbel et al., 2013; Frank et al., 2005; Holroyd & Krigolson, 2007; van der
984 Helden et al., 2010). These findings support a prominent theory purporting that the
985 FRN/RP is a reflection of reinforcement learning processes in the anterior cingulate
986 cortex driven by phasic dopamine reward prediction error signals (Holroyd & Coles,
987 2002; Walsh & Anderson, 2012). Contrary to our hypothesis, we observed no effects of

988 levodopa on the FRN/RP in response to reinforcement feedback. Previous studies have
989 supported a link between dopamine and the FRN/RP, although results have been
990 mixed. FRN/RP amplitude has been shown to be impaired in Parkinson's disease
991 patients with apathy (Martínez-Horta et al., 2014). Brown et al. (2020) found that the
992 reward positivity was impaired in Parkinson's disease patients relative to controls ON
993 levodopa but not OFF levodopa, consistent with the dopamine overdose hypothesis. In
994 healthy participants, the dopamine antagonist haloperidol has shown mixed results in
995 reducing the amplitude of the reward positivity (Forster et al., 2017; Schutte et al.,
996 2020). Mueller et al. (2014) found that the D2 receptor dopamine antagonist sulpiride
997 had opposite effects on FRN/RP amplitude depending on a genotype variant that
998 regulates prefrontal dopamine levels. They suggested a u-shaped relationship between
999 dopamine release in the prefrontal cortex and FRN/RP amplitude mediated by the
1000 balance between D1 and D2 receptor activation. Because the effect of dopamine
1001 manipulation on the FRN/RP seems to depend on genetic differences in baseline
1002 dopamine release, one possibility is that levodopa in the current study had inconsistent
1003 effects on different subgroups of participants that cancelled each other in the group
1004 average.

1005
1006 *Force field adaptation task:* Participants reliably adapted to the clockwise force field
1007 imposed in blocks FF1a and FF1b, and we found no evidence that adaptation was
1008 affected by levodopa. This was expected as force field adaptation is thought to rely
1009 primarily on sensory error-based learning mechanisms involving the cerebellum.
1010 Savings and interference effects have been accounted for by an additional process
1011 involving operant reinforcement of adapted motor commands upon repetition of
1012 successful reaches (Huang et al., 2011). These distinctions are supported by findings
1013 that cerebellar degeneration impairs force field adaptation while Parkinson's disease
1014 patients are spared in initial adaptation but display deficient savings and interference
1015 (Bédard & Sanes, 2011; Leow et al., 2012, 2013; Maschke et al., 2004; Jordan A.
1016 Taylor et al., 2010). Thus, we hypothesized that dopaminergic perturbation by levodopa
1017 would impair savings and interference while leaving initial adaptation intact. We found
1018 no effect of levodopa on savings or interference. Impaired savings may therefore be a
1019 specific effect of Parkinson's disease as opposed to a side-effect of levodopa. This is
1020 consistent with the findings of Marinelli et al. (2009), who observed a lack of savings
1021 effects in drug-naive and off-medication PD patients. An important limitation is that our
1022 experimental protocol was likely insufficient to produce savings or interference even in
1023 the control group, as we observed unreliable evidence of savings overall. Savings and
1024 interference have been shown to depend on sufficient repetition of the adapted
1025 movements to produce reinforcement of the adapted movements (Huang et al., 2011;
1026 Orban de Xivry & Lefèvre, 2015). Because the current study involved reaches to 8
1027 different targets, repetition and each individual target was limited relative to single target
1028 experiments.

1029
1030 *Conclusions:* As we expected, sensory error-based motor adaptation induced by
1031 visuomotor rotations and force field perturbations was not vulnerable to disruption of
1032 dopamine signaling by levodopa. This supports the notion that sensory error-based
1033 learning is driven by circuits involving cerebellar and sensorimotor cortex distinct from

1034 dopaminergic reinforcement learning mechanisms. Contrary to our hypotheses, we did
1035 not observe effects of levodopa on reward-based motor learning or the FRN/RP ERP
1036 component, which have both been theorized to depend on dopaminergic signaling of
1037 reward prediction error. The dopamine overdose hypothesis suggests that levodopa
1038 impairs stimulus-response reinforcement learning processes in the ventral striatum.
1039 Reward-based motor adaptation may instead depend on distinct reinforcement learning
1040 circuits that are not disrupted by levodopa such as cortical reward learning mechanisms
1041 or dopaminergic projections to the dorsal striatum.

1042 **Tables**
1043

Measure	Placebo	Levodopa
Heart Rate	Pre: 76.24 (SD: 11.29) Post: 69.60 (SD: 7.27)	Pre: 77.55 (SD: 8.41) Post: 71.53 (SD: 6.92)
Systolic	Pre: 104.43 (SD: 9.01) Post: 104.20 (SD: 6.47)	Pre: 103.95 (SD: 8.34) Post: 102.79 (SD: 8.70)
Diastolic	Pre: 72.14 (SD: 5.14) Post: 73.20 (SD: 4.55)	Pre: 70.55 (SD: 6.81) Post: 69.74 (SD: 6.04)
Alertness	Pre: 64.58 (SD: 8.38) Post: 47.99 (SD: 15.43)	Pre: 58.20 (SD: 11.79) Post: 48.16 (SD: 15.33)
Response Time	RL: 464.09 (SD: 140.05) VMR: 445.91 (SD: 120.96)	RL: 484.01 (SD: 149.00) VMR: 460.24 (SD: 133.04)
Movement Time	RL: 548.17 (SD: 37.04) VMR: 547.90 (SD: 34.92)	RL: 547.14 (SD: 35.28) VMR: 546.43 (SD: 40.52)

1044
1045 *Table 1: Control measurements from experiment 1. Heart rate (bpm). Systolic blood*
1046 *pressure (mm Hg). Diastolic blood pressure (mm Hg). Alertness, Bond-Lader visual*
1047 *analog scale alertness measure. Response Time, latency between go cue and hand*
1048 *exiting the start position (ms). Movement Time, duration of movement (ms). RL, reward*
1049 *learning task. VMR, visuomotor rotation task.*

1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066

Measure	Placebo	Levodopa
<i>n</i>	19	19
<i>n</i> female	9	10
Age	21.2 (SD: 2.5)	22.2 (SD: 3.4 years)
Heart Rate	Pre: 75.1 (SD: 9.5) Post: 66.2 (SD: 10.2)	Pre: 71.6842 (SD: 12.8) Post: 65.7 (SD: 11.3)
Systolic	Pre: 109.2 (SD: 15.4) Post: 104.8 (SD: 14.5)	Pre: 108.4 (SD: 11.4) Post: 99.7 (SD: 10.1)
Diastolic	Pre: 72.0 (SD: 10.2) Post: 70.1 (SD: 10.2)	Pre: 73.2 (SD: 15.5) Post: 67.0 (SD: 8.2)
Alertness	Pre: 31.3 (SD: 15.3) Post: 39.4 (SD: 17.0)	Pre: 27.1 (SD: 11.0) Post: 43.4 (SD: 12.7)
Peak Velocity	0.43 (SD = 0.01)	0.43 (SD = 0.02)

1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091

Table 2: Control measurements from Experiment 2. Heart rate (bpm). Systolic blood pressure (mm Hg). Diastolic blood pressure (mm Hg). Alertness, Bond-Lader visual analog scale alertness measure. Peak Velocity, maximum tangential velocity of the hand averaged across trials (m/s).

One Sample T-Tests

Placebo Non-Catch Trials	t	df	p	BF	Sample Mean	95% CI for Sample Mean	
						Lower	Upper
early adaptation	10.60	18	3.62e -9	6.36e +6	0.47	0.38	0.56
late adaptation	12.54	18	2.48e -10	7.72e +7	0.62	0.52	0.73
early savings	1.56	18	0.14	1.23	0.05	-0.02	0.13
late savings	0.70	18	0.50	0.44	0.02	-0.04	0.08
early after-effects	9.06	18	4.00e -8	688519.55	0.31	0.24	0.38
late after-effects	3.78	18	1.37e -3	56.24	0.09	0.04	0.14
early adaptation (interference)	11.46	18	1.06e -9	2.00e +7	0.76	0.62	0.89
late adaptation (interference)	15.70	18	5.98e -12	2.51e +9	1.18	1.02	1.34
Levodopa Non-Catch Trials	t	df	p	BF	Sample Mean	Lower	Upper
early adaptation	8.76	18	6.61e -8	432847.50	0.46	0.35	0.57
late adaptation	10.42	18	4.71e -9	4.99e +6	0.67	0.53	0.80
early savings	1.67	18	0.11	1.43	0.06	-0.02	0.14
late savings	-0.40	18	0.70	0.18	-0.01	-0.07	0.05
early after-effects	10.84	18	2.56e -9	8.79e +6	0.31	0.25	0.37
late after-effects	3.94	18	9.66e -4	76.15	0.08	0.04	0.12
early adaptation (interference)	6.59	18	3.42e -6	11657.42	0.61	0.42	0.81
late adaptation (interference)	11.12	18	1.70e -9	1.28e +7	1.02	0.83	1.21
Placebo Catch Trials	t	df	p	BF	Sample Mean	Lower	Upper
early adaptation	9.25	17	4.82e -8	574167.17	0.73	0.57	0.90
late adaptation	7.90	18	2.92e -7	110521.90	0.94	0.69	1.19
early savings	0.36	17	0.72	0.33	0.04	-0.20	0.28
late savings	1.54	18	0.14	1.20	0.27	-0.10	0.63
early adaptation (interference)	5.17	18	6.37e -5	837.09	0.82	0.49	1.15
late adaptation (interference)	7.68	18	4.33e -7	77010.30	1.36	0.99	1.74
Levodopa Catch Trials	t	df	p	BF	Sample Mean	Lower	Upper
early adaptation	9.12	18	3.62e -8	755029.63	0.68	0.52	0.83
late adaptation	14.40	18	2.54e -11	6.48e +8	0.96	0.82	1.10
early savings	-0.33	18	0.75	0.19	-0.03	-0.21	0.15
late savings	0.99	18	0.33	0.60	0.09	-0.11	0.29
early adaptation (interference)	6.42	18	4.84e -6	8524.02	0.92	0.62	1.22
late adaptation (interference)	9.03	18	4.20e -8	657919.38	1.30	1.00	1.60

Independent Samples T-Tests

Placebo vs Levodopa Non-Catch Trials	t	df	p	BF	Mean Diff.	95% CI for Mean Difference	
						Lower	Upper
early adaptation	0.22	36	0.83	0.37	0.01	-0.12	0.15
late adaptation	-0.57	36	0.57	0.22	-0.05	-0.21	0.12
early savings	-0.16	36	0.87	0.28	-7.98e -3	-0.11	0.09
late savings	0.77	36	0.45	0.59	0.03	-0.05	0.11
early after-effects	0.02	36	0.99	0.32	8.12e -4	-0.09	0.09
late after-effects	0.28	36	0.78	0.39	8.67e -3	-0.05	0.07
early adaptation (interference)	1.23	36	0.23	0.16	0.14	-0.09	0.37
late adaptation (interference)	1.38	36	0.18	0.15	0.16	-0.08	0.40
Placebo vs Levodopa Catch Trials	t	df	p	BF	Mean Diff.	Lower	Upper
early adaptation	0.51	35	0.61	0.47	0.06	-0.16	0.28
late adaptation	-0.12	36	0.90	0.29	-0.02	-0.29	0.26
early savings	0.49	35	0.63	0.47	0.07	-0.22	0.36
late savings	0.87	36	0.39	0.66	0.17	-0.23	0.57
early adaptation (interference)	-0.46	36	0.65	0.45	-0.10	-0.53	0.33
late adaptation (interference)	0.29	36	0.77	0.26	0.07	-0.40	0.53

1092
1093
1094
1095
1096


Table 2: Statistical results for experiment 2. In one-sample T-Tests, the null hypothesis was that the mean was equal to zero. T, T-statistic. DF, degrees of freedom. P, P-value. BF, Bayes factor in favor of the alternative hypothesis. 95% CI, frequentist confidence interval. Mean differences are computed as placebo-levodopa. Bayes factors were computed using one-tailed default

1097 priors for the alternative hypothesis. In all one-sample T-Tests, the alternative hypothesis was
1098 that the population mean is greater than zero. For independent T-Tests, the alternative
1099 hypothesis stated that adaptation with interference would be greater in the levodopa group than
1100 the placebo group. For all other independent T-tests, the alternative hypothesis stated that the
1101 measure of interest would be smaller in the levodopa group than the placebo group.

1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137

1138 **Figures**

1139




1140

1141

1142 **Figure 1.** Experimental setup. Top: Apparatus used in both experiments. Participants
1143 reached to visual targets while holding the handle of a robotic arm. Vision of the arm
1144 was obscured by a screen that displayed visual information related to the task. Bottom:
1145 Illustrations of visual display in experiment 1. **A**, Participants made outward reaching
1146 movements from a start position at body midline to a visual target. **B**, During reaches,
1147 hand position was hidden but an arc-shaped cursor indicated the extent of the reach
1148 without revealing reach angle. Feedback was provided at reach end point. **C**, In the
1149 reward learning task, binary feedback represented whether reaches were successful or
1150 unsuccessful in hitting the target by turning green or red, respectively. Reach adaptation
1151 was induced by providing reward for movements that did not necessarily correspond to


1152 the visual target. **D**, In the visuomotor rotation task, cursor feedback represented the
1153 end-point position of the hand. Adaptation was induced by shifting feedback relative to
1154 the actual reach angle by rotating it about the start position.

1155



1156

1157 **Figure 2.** Reward-based motor adaptation (n=21). The time series show group average
1158 reach angles in the reward learning task across trials (Shaded region: \pm SEM). After
1159 both placebo and levodopa administration, participants completed a block in each
1160 direction of intended learning condition [clockwise (CW) and counterclockwise (CCW)].
1161 Trials 1-11 were baseline trials without reinforcement feedback, and are not shown.
1162 Individual data points on the right show the average reach angles across trials in each
1163 condition for each participant (CCW: solid markers, CW: open markers, black: placebo,
1164 red: L-Dopa). Box plots summarize the distributions of individual data using circular
1165 markers to indicate the medians, thick lines to indicate interquartile ranges, and thin
1166 lines to indicate full ranges.



1167

1168


1169

1170

1171

1172


Figure 3. Reward induced modulation of trial-by-trial variability of reach angle (n=21). The log transformed variance of trial-by-trial changes in reach angle (deg) following reward and non-reward are plotted for each participant following administration of levodopa (A) and placebo (B).



1173

1174

1175 **Figure 4.** Sensory error-based motor adaptation (n=21). The average change in reach
1176 angle between subsequent pairs of trials is plotted for each size and direction of rotation
1177 imposed on the preceding trial. The average change in reach angle is in all cases
1178 opposite to the rotation, indicating that participants adapted their reaches to counteract
1179 the perturbations. Individual data points show average changes in reach angle across
1180 trials for each participant. Lines show average change in reach angle across
1181 participants (Error bars: \pm SEM).




1182

1183

1184 **Figure 5.** Event-related potentials elicited by reinforcement feedback (n=20). **A**, Grand
1185 averaged ERPs recorded from electrode FCz. ERPs are aligned to reinforcement
1186 feedback presentation (0 ms: vertical grey line). Horizontal grey bar indicates time
1187 window for FRN/RP analysis (267-317ms). Trials were selected by reinforcement
1188 outcome (reward or non-reward) and drug condition (levodopa or placebo) for ERP
1189 averaging. **B**, ERP amplitude during the FRN/RP time window. Individual participants'
1190 data show amplitude following reward, non-reward, and the difference [(reward) - (non-
1191 reward)]. Boxplots indicate the median (circular markers), the interquartile range (thick
1192 bars) and the range (thin lines). **C**, Trial averaged ERPs recorded from electrode Pz.
1193 Horizontal grey bars indicate time windows for P300 analysis (Reward: 294-344ms,
1194 Non-reward: 346-396ms). **D**, ERP amplitudes during the P300 time windows, as in B.


1195



1196

1197 **Figure 6.** Event-related potentials elicited by endpoint cursor feedback (n=20). **A**, Grand
1198 averaged ERPs recorded from electrode FCz. ERPs are aligned to endpoint cursor
1199 feedback presentation (0 ms: vertical gray line). Horizontal grey bar indicates time
1200 window for FRN/RP analysis (267-317ms). Trials were selected for feedback rotation
1201 (0°, ±2°, or ±4°) and drug condition (levodopa or placebo) for ERP averaging. **B**, ERP
1202 amplitude during the FRN/RP time window. Individual participants' data show amplitude
1203 following unrotated feedback as well as feedback rotated by ±2°, and ±4°. Differences in
1204 ERP amplitude between rotated and unrotated feedback are also shown for each
1205 participant. Boxplots indicate the median (circular markers), the interquartile range (thick
1206 bars) and the range (thin lines). **C**, Trial averaged ERPs recorded from electrode Pz.
1207 Horizontal grey bars indicate time window for P300 analysis (292-342 ms). **D**, ERP
1208 amplitudes during the P300 time windows, as in B.

1209




1210

1211

1212 **Figure 7.** Perpendicular deviation of reach trajectory during non-catch trial reaches.

1213 Average perpendicular deviation of the hand trajectory within bins consisting of 8 trials
1214 each is shown in cm (Shaded region: \pm SEM). The placebo condition is shown in black
1215 (n=19), and the levodopa condition is shown in red (n=19). Perpendicular deviation was
1216 measured on each trial at peak tangential velocity. Trials 6, 24, 35, 50, 71, and 91 of
1217 each block were catch trials, and were excluded from the corresponding bins. In *null*
1218 *field A* and *null field B*, the robot did not apply external forces to the hand during
1219 reaches. In *force field 1A* and *force field 1B*, participants made reaches in a clockwise
1220 force field. In *force field 2* participants made reaches in a counterclockwise force field.

1221



1222

1223

1224

1225

1226

1227

1228

1229


1230

1231

1232

1233

Figure 8. Perpendicular deviation of reach trajectory during catch trials. Perpendicular deviation of the hand trajectory, measured at peak tangential velocity, is shown in cm (Error bars: \pm SEM). The placebo condition is shown in black (n=19), and the levodopa condition is shown in red (n=19). Catch trials occurred on trials 6, 24, 35, 50, 71, and 91 of each block. In *null field A* and *null field B*, the robot did not apply external forces to the hand during reaches. In *force field 1A* and *force field 1B*, participants made reaches in a clockwise force field. In *force field 2* participants made reaches in a counterclockwise force field.



1234
1235
1236

1237 **Figure 9.** Adaptation effects in non-catch trials **A**, and catch trials **B**. Data points show
1238 effects for individual participants, box plots show the median, interquartile range, and
1239 full range. Effects are contrasts computed using perpendicular deviation (PD) of reach
1240 trajectory (cm), such that zero corresponds to no effect. Adaptation: change in PD
1241 during FF1a. Savings: difference in PD between FF1a and FF1b. After-effects:
1242 difference in PD between Nfb and baseline from NFa. Adaptation w/ interference:
1243 change in PD during FF2.

1244 **References**

1245

1246 Adams, R. A., Shipp, S., & Friston, K. J. (2013). Predictions not commands: Active inference in

1247 the motor system. *Brain Structure & Function*, 218(3), 611–643.

1248 <https://doi.org/10.1007/s00429-012-0475-5>

1249 Arbel, Y., Goforth, K., & Donchin, E. (2013). The Good, the Bad, or the Useful? The

1250 Examination of the Relationship between the Feedback-related Negativity (FRN) and

1251 Long-term Learning Outcomes. *Journal of Cognitive Neuroscience*, 25(8), 1249–1260.

1252 https://doi.org/10.1162/jocn_a_00385

1253 Aziz, J. R., MacLean, S. J., Krigolson, O. E., & Eskes, G. A. (2020). Visual Feedback Modulates

1254 Aftereffects and Electrophysiological Markers of Prism Adaptation. *Frontiers in Human*

1255 *Neuroscience*, 14. <https://doi.org/10.3389/fnhum.2020.00138>

1256 Babayan, B. M., Uchida, N., & Gershman, S. J. (2018). Belief state representation in the

1257 dopamine system. *Nature Communications*, 9(1), 1891. [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-018-04397-0)

1258 [018-04397-0](https://doi.org/10.1038/s41467-018-04397-0)

1259 Bayer, H. M., & Glimcher, P. W. (2005). Midbrain Dopamine Neurons Encode a Quantitative

1260 Reward Prediction Error Signal. *Neuron*, 47(1), 129–141.

1261 <https://doi.org/10.1016/j.neuron.2005.05.020>

1262 Beato, R., Levy, R., Pillon, B., Vidal, C., du Montcel, S. T., Deweer, B., Bonnet, A.-M., Houeto,

1263 J.-L., Dubois, B., & Cardoso, F. (2008). Working memory in Parkinson's disease

1264 patients: Clinical features and response to levodopa. *Arquivos De Neuro-Psiquiatria*,

1265 66(2A), 147–151. <https://doi.org/10.1590/s0004-282x2008000200001>

1266 Becker, M. P. I., Nitsch, A. M., Miltner, W. H. R., & Straube, T. (2014). A single-trial estimation

1267 of the feedback-related negativity and its relation to BOLD responses in a time-

- 1268 estimation task. *The Journal of Neuroscience: The Official Journal of the Society for*
1269 *Neuroscience*, 34(8), 3005–3012. <https://doi.org/10.1523/JNEUROSCI.3684-13.2014>
- 1270 Bédard, P., & Sanes, J. N. (2011). Basal ganglia-dependent processes in recalling learned visual-
1271 motor adaptations. *Experimental Brain Research*, 209(3), 385–393.
1272 <https://doi.org/10.1007/s00221-011-2561-y>
- 1273 Bernardi, N. F., Darainy, M., & Ostry, D. J. (2015). Somatosensory Contribution to the Initial
1274 Stages of Human Motor Learning. *Journal of Neuroscience*, 35(42), 14316–14326.
1275 <https://doi.org/10.1523/JNEUROSCI.1344-15.2015>
- 1276 Bhanpuri, N. H., Okamura, A. M., & Bastian, A. J. (2013). Predictive Modeling by the
1277 Cerebellum Improves Proprioception. *Journal of Neuroscience*, 33(36), 14301–14306.
1278 <https://doi.org/10.1523/JNEUROSCI.0784-13.2013>
- 1279 Bledowski, C., Prvulovic, D., Hoechstetter, K., Scherg, M., Wibral, M., Goebel, R., & Linden,
1280 D. E. J. (2004). Localizing P300 generators in visual target and distractor processing: A
1281 combined event-related potential and functional magnetic resonance imaging study. *The*
1282 *Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 24(42),
1283 9353–9360. <https://doi.org/10.1523/JNEUROSCI.1897-04.2004>
- 1284 Bock, O., Schneider, S., & Bloomberg, J. (2001). Conditions for interference versus facilitation
1285 during sequential sensorimotor adaptation. *Experimental Brain Research*, 138(3), 359–
1286 365. <https://doi.org/10.1007/s002210100704>
- 1287 Bond, A., & Lader, M. (1974). The use of analogue scales in rating subjective feelings. *British*
1288 *Journal of Medical Psychology*, 47(3), 211–218. [https://doi.org/10.1111/j.2044-](https://doi.org/10.1111/j.2044-8341.1974.tb02285.x)
1289 [8341.1974.tb02285.x](https://doi.org/10.1111/j.2044-8341.1974.tb02285.x)

- 1290 Brooks, J. L., Zoumpoulaki, A., & Bowman, H. (2017). Data-driven region-of-interest selection
1291 without inflating Type I error rate. *Psychophysiology*, *54*(1), 100–113.
1292 <https://doi.org/10.1111/psyp.12682>
- 1293 Brown, D. R., Richardson, S. P., & Cavanagh, J. F. (2020). An EEG marker of reward
1294 processing is diminished in Parkinson’s disease. *Brain Research*, *1727*, 146541.
1295 <https://doi.org/10.1016/j.brainres.2019.146541>
- 1296 Calhoun, V. D., Adali, T., Pearlson, G. D., & Kiehl, K. A. (2006). Neuronal chronometry of
1297 target detection: Fusion of hemodynamic and event-related potential data. *NeuroImage*,
1298 *30*(2), 544–553. <https://doi.org/10.1016/j.neuroimage.2005.08.060>
- 1299 Carlson, J. M., Foti, D., Mujica-Parodi, L. R., Harmon-Jones, E., & Hajcak, G. (2011). Ventral
1300 striatal and medial prefrontal BOLD activation is correlated with reward-related
1301 electrocortical activity: A combined ERP and fMRI study. *NeuroImage*, *57*(4), 1608–
1302 1616. <https://doi.org/10.1016/j.neuroimage.2011.05.037>
- 1303 Cashaback, J. G. A., Lao, C. K., Palidis, D. J., Coltman, S. K., McGregor, H. R., & Gribble, P. L.
1304 (2019). The gradient of the reinforcement landscape influences sensorimotor learning.
1305 *PLOS Computational Biology*, *15*(3), e1006839.
1306 <https://doi.org/10.1371/journal.pcbi.1006839>
- 1307 Cashaback, J. G. A., McGregor, H. R., Mohatarem, A., & Gribble, P. L. (2017). Dissociating
1308 error-based and reinforcement-based loss functions during sensorimotor learning. *PLoS*
1309 *Computational Biology*, *13*(7), e1005623. <https://doi.org/10.1371/journal.pcbi.1005623>
- 1310 Chu, C.-L., Lee, I. H., Chi, M. H., Chen, K. C., Chen, P. S., Yao, W. J., Chiu, N. T., & Yang, Y.
1311 K. (2018). Availability of dopamine transporters and auditory P300 abnormalities in

- 1312 adults with attention-deficit hyperactivity disorder: Preliminary results. *CNS Spectrums*,
1313 23(4), 264–270. <https://doi.org/10.1017/S1092852917000049>
- 1314 Codol, O., Holland, P. J., & Galea, J. M. (2018). The relationship between reinforcement and
1315 explicit control during visuomotor adaptation. *Scientific Reports*, 8(1), 9121.
1316 <https://doi.org/10.1038/s41598-018-27378-1>
- 1317 Cools, R., Barker, R. A., Sahakian, B. J., & Robbins, T. W. (2001). Enhanced or impaired
1318 cognitive function in Parkinson's disease as a function of dopaminergic medication and
1319 task demands. *Cerebral Cortex (New York, N.Y.: 1991)*, 11(12), 1136–1143.
1320 <https://doi.org/10.1093/cercor/11.12.1136>
- 1321 Cools, Roshan, Altamirano, L., & D'Esposito, M. (2006). Reversal learning in Parkinson's
1322 disease depends on medication status and outcome valence. *Neuropsychologia*, 44(10),
1323 1663–1673. <https://doi.org/10.1016/j.neuropsychologia.2006.03.030>
- 1324 Cools, Roshan, Barker, R. A., Sahakian, B. J., & Robbins, T. W. (2003). L-Dopa medication
1325 remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's
1326 disease. *Neuropsychologia*, 41(11), 1431–1441. [https://doi.org/10.1016/s0028-](https://doi.org/10.1016/s0028-3932(03)00117-9)
1327 [3932\(03\)00117-9](https://doi.org/10.1016/s0028-3932(03)00117-9)
- 1328 Cools, Roshan, Lewis, S. J. G., Clark, L., Barker, R. A., & Robbins, T. W. (2007). L-DOPA
1329 disrupts activity in the nucleus accumbens during reversal learning in Parkinson's
1330 disease. *Neuropsychopharmacology: Official Publication of the American College of*
1331 *Neuropsychopharmacology*, 32(1), 180–189. <https://doi.org/10.1038/sj.npp.1301153>
- 1332 Cooper, J. A., Sagar, H. J., Doherty, S. M., Jordan, N., Tidswell, P., & Sullivan, E. V. (1992).
1333 Different effects of dopaminergic and anticholinergic therapies on cognitive and motor

- 1334 function in Parkinson's disease. A follow-up study of untreated patients. *Brain: A*
1335 *Journal of Neurology*, 115 (Pt 6), 1701–1725. <https://doi.org/10.1093/brain/115.6.1701>
- 1336 Costa, A., Peppe, A., Dell'Agnello, G., Carlesimo, G. A., Murri, L., Bonuccelli, U., &
1337 Caltagirone, C. (2003). Dopaminergic modulation of visual-spatial working memory in
1338 Parkinson's disease. *Dementia and Geriatric Cognitive Disorders*, 15(2), 55–66.
1339 <https://doi.org/10.1159/000067968>
- 1340 Daw, N. D., Gershman, S. J., Seymour, B., Dayan, P., & Dolan, R. J. (2011). Model-based
1341 influences on humans' choices and striatal prediction errors. *Neuron*, 69(6), 1204–1215.
1342 <https://doi.org/10.1016/j.neuron.2011.02.027>
- 1343 Daw, N. D., & Tobler, P. N. (2014). Chapter 15 - Value Learning through Reinforcement: The
1344 Basics of Dopamine and Reinforcement Learning. In P. W. Glimcher & E. Fehr (Eds.),
1345 *Neuroeconomics (Second Edition)* (pp. 283–298). Academic Press.
1346 <https://doi.org/10.1016/B978-0-12-416008-8.00015-2>
- 1347 Delorme, A., & Makeig, S. (2004). EEGLAB: An open source toolbox for analysis of single-trial
1348 EEG dynamics including independent component analysis. *Journal of Neuroscience*
1349 *Methods*, 134(1), 9–21. <https://doi.org/10.1016/j.jneumeth.2003.10.009>
- 1350 Deserno, L., Huys, Q. J. M., Boehme, R., Buchert, R., Heinze, H.-J., Grace, A. A., Dolan, R. J.,
1351 Heinz, A., & Schlagenhauf, F. (2015). Ventral striatal dopamine reflects behavioral and
1352 neural signatures of model-based control during sequential decision making. *Proceedings*
1353 *of the National Academy of Sciences of the United States of America*, 112(5), 1595–1600.
1354 <https://doi.org/10.1073/pnas.1417219112>

- 1355 Dhawale, A. K., Miyamoto, Y. R., Smith, M. A., & Ölveczky, B. P. (2019). Adaptive Regulation
1356 of Motor Variability. *Current Biology*, 29(21), 3551-3562.e7.
1357 <https://doi.org/10.1016/j.cub.2019.08.052>
- 1358 Diedrichsen, J., Hashambhoy, Y., Rane, T., & Shadmehr, R. (2005). Neural Correlates of Reach
1359 Errors. *Journal of Neuroscience*, 25(43), 9919–9931.
1360 <https://doi.org/10.1523/JNEUROSCI.1874-05.2005>
- 1361 Dolan, R. J., & Dayan, P. (2013). Goals and Habits in the Brain. *Neuron*, 80(2), 312–325.
1362 <https://doi.org/10.1016/j.neuron.2013.09.007>
- 1363 Doll, B. B., Bath, K. G., Daw, N. D., & Frank, M. J. (2016). Variability in Dopamine Genes
1364 Dissociates Model-Based and Model-Free Reinforcement Learning. *The Journal of*
1365 *Neuroscience: The Official Journal of the Society for Neuroscience*, 36(4), 1211–1222.
1366 <https://doi.org/10.1523/JNEUROSCI.1901-15.2016>
- 1367 Emeric, E. E., Brown, J. W., Leslie, M., Pouget, P., Stuphorn, V., & Schall, J. D. (2008).
1368 Performance monitoring local field potentials in the medial frontal cortex of primates:
1369 Anterior cingulate cortex. *Journal of Neurophysiology*, 99(2), 759–772.
1370 <https://doi.org/10.1152/jn.00896.2006>
- 1371 Enge, S., Mothes, H., Fleischhauer, M., Reif, A., & Strobel, A. (2017). Genetic variation of
1372 dopamine and serotonin function modulates the feedback-related negativity during
1373 altruistic punishment. *Scientific Reports*, 7(1), 2996. [https://doi.org/10.1038/s41598-017-](https://doi.org/10.1038/s41598-017-02594-3)
1374 [02594-3](https://doi.org/10.1038/s41598-017-02594-3)
- 1375 Feigin, A., Ghilardi, M. F., Carbon, M., Edwards, C., Fukuda, M., Dhawan, V., Margouleff, C.,
1376 Ghez, C., & Eidelberg, D. (2003). Effects of levodopa on motor sequence learning in

- 1377 Parkinson's disease. *Neurology*, *60*(11), 1744–1749.
- 1378 <https://doi.org/10.1212/01.wnl.0000072263.03608.42>
- 1379 Flöel, A., Breitenstein, C., Hummel, F., Celnik, P., Gingert, C., Sawaki, L., Knecht, S., & Cohen,
1380 L. G. (2005). Dopaminergic influences on formation of a motor memory. *Annals of*
1381 *Neurology*, *58*(1), 121–130. <https://doi.org/10.1002/ana.20536>
- 1382 Forster, S. E., Zirnheld, P., Shekhar, A., Steinhauer, S. R., O'Donnell, B. F., & Hetrick, W. P.
1383 (2017). Event-related potentials reflect impaired temporal interval learning following
1384 haloperidol administration. *Psychopharmacology*, *234*(17), 2545–2562.
1385 <https://doi.org/10.1007/s00213-017-4645-2>
- 1386 Foti, D., Weinberg, A., Dien, J., & Hajcak, G. (2011). Event-related potential activity in the
1387 basal ganglia differentiates rewards from nonrewards: Temporospacial principal
1388 components analysis and source localization of the feedback negativity. *Human Brain*
1389 *Mapping*, *32*(12), 2207–2216. <https://doi.org/10.1002/hbm.21182>
- 1390 Frank, M. J., Seeberger, L. C., & O'reilly, R. C. (2004). By carrot or by stick: Cognitive
1391 reinforcement learning in parkinsonism. *Science (New York, N.Y.)*, *306*(5703), 1940–
1392 1943. <https://doi.org/10.1126/science.1102941>
- 1393 Frank, M. J., Woroach, B. S., & Curran, T. (2005). Error-Related Negativity Predicts
1394 Reinforcement Learning and Conflict Biases. *Neuron*, *47*(4), 495–501.
1395 <https://doi.org/10.1016/j.neuron.2005.06.020>
- 1396 Galea, J. M., Mallia, E., Rothwell, J., & Diedrichsen, J. (2015). The dissociable effects of
1397 punishment and reward on motor learning. *Nature Neuroscience*, *18*(4), 597–602.
1398 <https://doi.org/10.1038/nn.3956>

- 1399 García-García, I., Zeighami, Y., & Dagher, A. (2017). Reward Prediction Errors in Drug
1400 Addiction and Parkinson's Disease: From Neurophysiology to Neuroimaging. *Current*
1401 *Neurology and Neuroscience Reports*, 17(6), 46. [https://doi.org/10.1007/s11910-017-](https://doi.org/10.1007/s11910-017-0755-9)
1402 0755-9
- 1403 Gardner, M. P. H., Schoenbaum, G., & Gershman, S. J. (2018). Rethinking dopamine as
1404 generalized prediction error. *Proceedings. Biological Sciences*, 285(1891).
1405 <https://doi.org/10.1098/rspb.2018.1645>
- 1406 Gehring, W. J., & Willoughby, A. R. (2002). The Medial Frontal Cortex and the Rapid
1407 Processing of Monetary Gains and Losses. *Science*, 295(5563), 2279–2282.
1408 <https://doi.org/10.1126/science.1066893>
- 1409 Gläscher, J., Daw, N., Dayan, P., & O'Doherty, J. P. (2010). States versus rewards: Dissociable
1410 neural prediction error signals underlying model-based and model-free reinforcement
1411 learning. *Neuron*, 66(4), 585–595. <https://doi.org/10.1016/j.neuron.2010.04.016>
- 1412 Graef, S., Biele, G., Krugel, L. K., Marzinzik, F., Wahl, M., Wotka, J., Klostermann, F., &
1413 Heekeren, H. R. (2010). Differential influence of levodopa on reward-based learning in
1414 Parkinson's disease. *Frontiers in Human Neuroscience*, 4, 169.
1415 <https://doi.org/10.3389/fnhum.2010.00169>
- 1416 Hansenne, M., Pitchot, W., Gonzalez Moreno, A., Papart, P., Timsit-Berthier, M., & Ansseau,
1417 M. (1995). Catecholaminergic function and P300 amplitude in major depressive disorder
1418 (P300 and catecholamines). *Electroencephalography and Clinical Neurophysiology*,
1419 96(2), 194–196. [https://doi.org/10.1016/0168-5597\(94\)00317-8](https://doi.org/10.1016/0168-5597(94)00317-8)
- 1420 Hauser, T. U., Iannaccone, R., Stämpfli, P., Drechsler, R., Brandeis, D., Walitza, S., & Brem, S.
1421 (2014). The feedback-related negativity (FRN) revisited: New insights into the

- 1422 localization, meaning and network organization. *NeuroImage*, *84*, 159–168.
- 1423 <https://doi.org/10.1016/j.neuroimage.2013.08.028>
- 1424 Hiebert, N. M., Seergobin, K. N., Vo, A., Ganjavi, H., & MacDonald, P. A. (2014).
- 1425 Dopaminergic therapy affects learning and impulsivity in Parkinson’s disease. *Annals of*
- 1426 *Clinical and Translational Neurology*, *1*(10), 833–843. <https://doi.org/10.1002/acn3.128>
- 1427 Holland, P., Codol, O., & Galea, J. M. (2018). Contribution of explicit processes to
- 1428 reinforcement-based motor learning. *Journal of Neurophysiology*, *119*(6), 2241–2255.
- 1429 <https://doi.org/10.1152/jn.00901.2017>
- 1430 Holland, P., Codol, O., Oxley, E., Taylor, M., Hamshire, E., Joseph, S., Huffer, L., & Galea, J.
- 1431 M. (2019). Domain-Specific Working Memory, But Not Dopamine-Related Genetic
- 1432 Variability, Shapes Reward-Based Motor Learning. *The Journal of Neuroscience*, *39*(47),
- 1433 9383–9396. <https://doi.org/10.1523/JNEUROSCI.0583-19.2019>
- 1434 Holroyd, C. B., & Coles, M. G. H. (2002). The neural basis of human error processing:
- 1435 Reinforcement learning, dopamine, and the error-related negativity. *Psychological*
- 1436 *Review*, *109*(4), 679–709. <https://doi.org/10.1037/0033-295X.109.4.679>
- 1437 Holroyd, C. B., & Krigolson, O. E. (2007). Reward prediction error signals associated with a
- 1438 modified time estimation task. *Psychophysiology*, *44*(6), 913–917.
- 1439 <https://doi.org/10.1111/j.1469-8986.2007.00561.x>
- 1440 Holroyd, C. B., Pakzad-Vaezi, K. L., & Krigolson, O. E. (2008). The feedback correct-related
- 1441 positivity: Sensitivity of the event-related brain potential to unexpected positive
- 1442 feedback. *Psychophysiology*, *45*(5), 688–697. [https://doi.org/10.1111/j.1469-](https://doi.org/10.1111/j.1469-8986.2008.00668.x)
- 1443 [8986.2008.00668.x](https://doi.org/10.1111/j.1469-8986.2008.00668.x)

- 1444 Huang, V. S., Haith, A., Mazzoni, P., & Krakauer, J. W. (2011). Rethinking Motor Learning and
1445 Savings in Adaptation Paradigms: Model-Free Memory for Successful Actions Combines
1446 with Internal Models. *Neuron*, *70*(4), 787–801.
1447 <https://doi.org/10.1016/j.neuron.2011.04.012>
- 1448 Ito, M. (2000). Mechanisms of motor learning in the cerebellum1. *Brain Research*, *886*(1–2),
1449 237–245. [https://doi.org/10.1016/S0006-8993\(00\)03142-5](https://doi.org/10.1016/S0006-8993(00)03142-5)
- 1450 Izawa, J., & Shadmehr, R. (2011). Learning from Sensory and Reward Prediction Errors during
1451 Motor Adaptation. *PLOS Computational Biology*, *7*(3), e1002012.
1452 <https://doi.org/10.1371/journal.pcbi.1002012>
- 1453 Jahanshahi, M., Wilkinson, L., Gahir, H., Dharmaindra, A., Dharmarinda, A., Dharminda, A., &
1454 Lagnado, D. A. (2010). Medication impairs probabilistic classification learning in
1455 Parkinson’s disease. *Neuropsychologia*, *48*(4), 1096–1103.
1456 <https://doi.org/10.1016/j.neuropsychologia.2009.12.010>
- 1457 Jocham, G., & Ullsperger, M. (2009). Neuropharmacology of performance monitoring.
1458 *Neuroscience and Biobehavioral Reviews*, *33*(1), 48–60.
1459 <https://doi.org/10.1016/j.neubiorev.2008.08.011>
- 1460 Johnson, J. F., Belyk, M., Schwartz, M., Pinheiro, A. P., & Kotz, S. A. (2019). The role of the
1461 cerebellum in adaptation: ALE meta-analyses on sensory feedback error. *Human Brain*
1462 *Mapping*, *40*(13), 3966–3981. <https://doi.org/10.1002/hbm.24681>
- 1463 Keysers, C., Gazzola, V., & Wagenmakers, E.-J. (2020). Using Bayes factor hypothesis testing
1464 in neuroscience to establish evidence of absence. *Nature Neuroscience*, *23*(7), 788–799.
1465 <https://doi.org/10.1038/s41593-020-0660-4>

- 1466 Kim, H. E., Parvin, D. E., & Ivry, R. B. (2019). The influence of task outcome on implicit motor
1467 learning. *ELife*, 8. <https://doi.org/10.7554/eLife.39882>
- 1468 Knecht, S., Breitenstein, C., Bushuven, S., Wailke, S., Kamping, S., Flöel, A., Zwitserlood, P., &
1469 Ringelstein, E. B. (2004). Levodopa: Faster and better word learning in normal humans.
1470 *Annals of Neurology*, 56(1), 20–26. <https://doi.org/10.1002/ana.20125>
- 1471 Kooij, K. van der, Wijdenes, L. O., Rigterink, T., Overvliet, K. E., & Smeets, J. B. J. (2018).
1472 Reward abundance interferes with error-based learning in a visuomotor adaptation task.
1473 *PLOS ONE*, 13(3), e0193002. <https://doi.org/10.1371/journal.pone.0193002>
- 1474 Krakauer, J. W., Ghilardi, M.-F., Mentis, M., Barnes, A., Veytsman, M., Eidelberg, D., & Ghez,
1475 C. (2004). Differential Cortical and Subcortical Activations in Learning Rotations and
1476 Gains for Reaching: A PET Study. *Journal of Neurophysiology*, 91(2), 924–933.
1477 <https://doi.org/10.1152/jn.00675.2003>
- 1478 Kuling, I. A., de Brouwer, A. J., Smeets, J. B. J., & Flanagan, J. R. (2019). Correcting for natural
1479 visuo-proprioceptive matching errors based on reward as opposed to error feedback does
1480 not lead to higher retention. *Experimental Brain Research*, 237(3), 735–741.
1481 <https://doi.org/10.1007/s00221-018-5456-3>
- 1482 Kulisevsky, J. (2000). Role of dopamine in learning and memory: Implications for the treatment
1483 of cognitive dysfunction in patients with Parkinson’s disease. *Drugs & Aging*, 16(5),
1484 365–379. <https://doi.org/10.2165/00002512-200016050-00006>
- 1485 Kwak, Y., Müller, M. L. T. M., Bohnen, N. I., Dayalu, P., & Seidler, R. D. (2010). Effect of
1486 dopaminergic medications on the time course of explicit motor sequence learning in
1487 Parkinson’s disease. *Journal of Neurophysiology*, 103(2), 942–949.
1488 <https://doi.org/10.1152/jn.00197.2009>

- 1489 Lange, K. W., Robbins, T. W., Marsden, C. D., James, M., Owen, A. M., & Paul, G. M. (1992).
1490 L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in
1491 tests sensitive to frontal lobe dysfunction. *Psychopharmacology*, *107*(2–3), 394–404.
1492 <https://doi.org/10.1007/BF02245167>
- 1493 Leow, L.-A., de Ruyg, A., Loftus, A. M., & Hammond, G. (2013). Different mechanisms
1494 contributing to savings and anterograde interference are impaired in Parkinson's disease.
1495 *Frontiers in Human Neuroscience*, *7*. <https://doi.org/10.3389/fnhum.2013.00055>
- 1496 Leow, L.-A., Loftus, A. M., & Hammond, G. R. (2012). Impaired savings despite intact initial
1497 learning of motor adaptation in Parkinson's disease. *Experimental Brain Research*,
1498 *218*(2), 295–304. <https://doi.org/10.1007/s00221-012-3060-5>
- 1499 Leow, L.-A., Marinovic, W., de Ruyg, A., & Carroll, T. J. (2018). Task errors contribute to
1500 implicit aftereffects in sensorimotor adaptation. *The European Journal of Neuroscience*,
1501 *48*(11), 3397–3409. <https://doi.org/10.1111/ejn.14213>
- 1502 Leow, L.-A., Marinovic, W., Ruyg, A. de, & Carroll, T. J. (2020). Task Errors Drive Memories
1503 That Improve Sensorimotor Adaptation. *Journal of Neuroscience*, *40*(15), 3075–3088.
1504 <https://doi.org/10.1523/JNEUROSCI.1506-19.2020>
- 1505 Lewis, S. J. G., Slabosz, A., Robbins, T. W., Barker, R. A., & Owen, A. M. (2005).
1506 Dopaminergic basis for deficits in working memory but not attentional set-shifting in
1507 Parkinson's disease. *Neuropsychologia*, *43*(6), 823–832.
1508 <https://doi.org/10.1016/j.neuropsychologia.2004.10.001>
- 1509 Li, Y., Wang, L.-Q., & Hu, Y. (2009). Localizing P300 generators in high-density event-related
1510 potential with fMRI. *Medical Science Monitor: International Medical Journal of*
1511 *Experimental and Clinical Research*, *15*(3), MT47-53.

- 1512 MacDonald, P. A., MacDonald, A. A., Seergobin, K. N., Tamjeedi, R., Ganjavi, H., Provost, J.-
1513 S., & Monchi, O. (2011). The effect of dopamine therapy on ventral and dorsal striatum-
1514 mediated cognition in Parkinson's disease: Support from functional MRI. *Brain: A*
1515 *Journal of Neurology*, 134(Pt 5), 1447–1463. <https://doi.org/10.1093/brain/awr075>
- 1516 MacLean, S. J., Hassall, C. D., Ishigami, Y., Krigolson, O. E., & Eskes, G. A. (2015). Using
1517 brain potentials to understand prism adaptation: The error-related negativity and the
1518 P300. *Frontiers in Human Neuroscience*, 9. <https://doi.org/10.3389/fnhum.2015.00335>
- 1519 Mantini, D., Corbetta, M., Perrucci, M. G., Romani, G. L., & Del Gratta, C. (2009). Large-scale
1520 brain networks account for sustained and transient activity during target detection.
1521 *NeuroImage*, 44(1), 265–274. <https://doi.org/10.1016/j.neuroimage.2008.08.019>
- 1522 Marco-Pallarés, J., Cucurell, D., Cunillera, T., Krämer, U. M., Càmara, E., Nager, W., Bauer, P.,
1523 Schüle, R., Schöls, L., Münte, T. F., & Rodriguez-Fornells, A. (2009). Genetic variability
1524 in the dopamine system (dopamine receptor D4, catechol-O-methyltransferase)
1525 modulates neurophysiological responses to gains and losses. *Biological Psychiatry*, 66(2),
1526 154–161. <https://doi.org/10.1016/j.biopsych.2009.01.006>
- 1527 Marinelli, L., Crupi, D., Di Rocco, A., Bove, M., Eidelberg, D., Abbruzzese, G., & Felice
1528 Ghilardi, M. (2009). Learning and consolidation of visuo-motor adaptation in Parkinson's
1529 disease. *Parkinsonism & Related Disorders*, 15(1), 6–11.
1530 <https://doi.org/10.1016/j.parkreldis.2008.02.012>
- 1531 Marini, P., Ramat, S., Ginestroni, A., & Paganini, M. (2003). Deficit of short-term memory in
1532 newly diagnosed untreated parkinsonian patients: Reversal after L-dopa therapy.
1533 *Neurological Sciences: Official Journal of the Italian Neurological Society and of the*

- 1534 *Italian Society of Clinical Neurophysiology*, 24(3), 184–185.
- 1535 <https://doi.org/10.1007/s10072-003-0121-3>
- 1536 Martínez-Horta, S., Riba, J., Bobadilla, R. F. de, Pagonabarraga, J., Pascual-Sedano, B.,
1537 Antonijoan, R. M., Romero, S., Mañanas, M. À., García-Sánchez, C., & Kulisevsky, J.
1538 (2014). Apathy in Parkinson's Disease: Neurophysiological Evidence of Impaired
1539 Incentive Processing. *Journal of Neuroscience*, 34(17), 5918–5926.
1540 <https://doi.org/10.1523/JNEUROSCI.0251-14.2014>
- 1541 Maschke, M., Gomez, C. M., Ebner, T. J., & Konczak, J. (2004). Hereditary cerebellar ataxia
1542 progressively impairs force adaptation during goal-directed arm movements. *Journal of*
1543 *Neurophysiology*, 91(1), 230–238. <https://doi.org/10.1152/jn.00557.2003>
- 1544 Mastriqt, N. M. van, Smeets, J. B. J., & Kooij, K. van der. (2020). Quantifying exploration in
1545 reward-based motor learning. *PLOS ONE*, 15(4), e0226789.
1546 <https://doi.org/10.1371/journal.pone.0226789>
- 1547 Mathewson, K. J., Dywan, J., Snyder, P. J., Tays, W. J., & Segalowitz, S. J. (2008). Aging and
1548 electrocortical response to error feedback during a spatial learning task.
1549 *Psychophysiology*, 45(6), 936–948. <https://doi.org/10.1111/j.1469-8986.2008.00699.x>
- 1550 Mazzoni, P., & Krakauer, J. W. (2006). An Implicit Plan Overrides an Explicit Strategy during
1551 Visuomotor Adaptation. *Journal of Neuroscience*, 26(14), 3642–3645.
1552 <https://doi.org/10.1523/JNEUROSCI.5317-05.2006>
- 1553 McDougle, S. D., Ivry, R. B., & Taylor, J. A. (2016). Taking Aim at the Cognitive Side of
1554 Learning in Sensorimotor Adaptation Tasks. *Trends in Cognitive Sciences*, 20(7), 535–
1555 544. <https://doi.org/10.1016/j.tics.2016.05.002>

- 1556 Mehler, D. M. A., Reichenbach, A., Klein, J., & Diedrichsen, J. (2017). Minimizing endpoint
1557 variability through reinforcement learning during reaching movements involving
1558 shoulder, elbow and wrist. *PloS One*, *12*(7), e0180803.
1559 <https://doi.org/10.1371/journal.pone.0180803>
- 1560 Miall, R. Chris, Christensen, L. O. D., Cain, O., & Stanley, J. (2007). Disruption of State
1561 Estimation in the Human Lateral Cerebellum. *PLOS Biology*, *5*(11), e316.
1562 <https://doi.org/10.1371/journal.pbio.0050316>
- 1563 Miall, R. Christopher, Jenkinson, N., & Kulkarni, K. (2004). Adaptation to rotated visual
1564 feedback: A re-examination of motor interference. *Experimental Brain Research*, *154*(2),
1565 201–210. <https://doi.org/10.1007/s00221-003-1630-2>
- 1566 Miltner, W. H., Braun, C. H., & Coles, M. G. (1997). Event-related brain potentials following
1567 incorrect feedback in a time-estimation task: Evidence for a “generic” neural system for
1568 error detection. *Journal of Cognitive Neuroscience*, *9*(6), 788–798.
1569 <https://doi.org/10.1162/jocn.1997.9.6.788>
- 1570 Mongeon, D., Blanchet, P., & Messier, J. (2013). Impact of Parkinson’s disease and
1571 dopaminergic medication on adaptation to explicit and implicit visuomotor perturbations.
1572 *Brain and Cognition*, *81*(2), 271–282. <https://doi.org/10.1016/j.bandc.2012.12.001>
- 1573 Montgomery, D. C., Peck, E. A., & Vining, G. G. (2021). *Introduction to Linear Regression*
1574 *Analysis*. John Wiley & Sons.
- 1575 Moustafa, A. A., Sherman, S. J., & Frank, M. J. (2008). A dopaminergic basis for working
1576 memory, learning and attentional shifting in Parkinsonism. *Neuropsychologia*, *46*(13),
1577 3144–3156. <https://doi.org/10.1016/j.neuropsychologia.2008.07.011>

- 1578 Mueller, E. M., Burgdorf, C., Chavanon, M.-L., Schweiger, D., Hennig, J., Wacker, J., &
1579 Stemmler, G. (2014). The COMT Val158Met polymorphism regulates the effect of a
1580 dopamine antagonist on the feedback-related negativity. *Psychophysiology*, *51*(8), 805–
1581 809. <https://doi.org/10.1111/psyp.12226>
- 1582 Mulert, C., Juckel, G., Giegling, I., Pogarell, O., Leicht, G., Karch, S., Mavrogiorgou, P., Möller,
1583 H.-J., Hegerl, U., & Rujescu, D. (2006). A Ser9Gly polymorphism in the dopamine D3
1584 receptor gene (DRD3) and event-related P300 potentials. *Neuropsychopharmacology:*
1585 *Official Publication of the American College of Neuropsychopharmacology*, *31*(6), 1335–
1586 1344. <https://doi.org/10.1038/sj.npp.1300984>
- 1587 Nikooyan, A. A., & Ahmed, A. A. (2014). Reward feedback accelerates motor learning. *Journal*
1588 *of Neurophysiology*, *113*(2), 633–646. <https://doi.org/10.1152/jn.00032.2014>
- 1589 Noble, E. P., Berman, S. M., Ozkaragoz, T. Z., & Ritchie, T. (1994). Prolonged P300 latency in
1590 children with the D2 dopamine receptor A1 allele. *American Journal of Human Genetics*,
1591 *54*(4), 658–668.
- 1592 Noohi, F., Boyden, N. B., Kwak, Y., Humfleet, J., Burke, D. T., Müller, M. L. T. M., Bohnen, N.
1593 I., & Seidler, R. D. (2014). Association of COMT val158met and DRD2 G>T genetic
1594 polymorphisms with individual differences in motor learning and performance in female
1595 young adults. *Journal of Neurophysiology*, *111*(3), 628–640.
1596 <https://doi.org/10.1152/jn.00457.2013>
- 1597 Olanow, W., Schapira, A. H., & Rascol, O. (2000). Continuous dopamine-receptor stimulation in
1598 early Parkinson's disease. *Trends in Neurosciences*, *23*(10 Suppl), S117-126.
1599 [https://doi.org/10.1016/s1471-1931\(00\)00030-6](https://doi.org/10.1016/s1471-1931(00)00030-6)

- 1600 Onur, Ö. A., Piefke, M., Lie, C.-H., Thiel, C. M., & Fink, G. R. (2011). Modulatory effects of
1601 levodopa on cognitive control in young but not in older subjects: A pharmacological
1602 fMRI study. *Journal of Cognitive Neuroscience*, *23*(10), 2797–2810.
1603 <https://doi.org/10.1162/jocn.2011.21603>
- 1604 Orban de Xivry, J.-J., & Lefèvre, P. (2015). Formation of model-free motor memories during
1605 motor adaptation depends on perturbation schedule. *Journal of Neurophysiology*, *113*(7),
1606 2733–2741. <https://doi.org/10.1152/jn.00673.2014>
- 1607 Otani, S., Daniel, H., Roisin, M.-P., & Crepel, F. (2003). Dopaminergic modulation of long-term
1608 synaptic plasticity in rat prefrontal neurons. *Cerebral Cortex (New York, N.Y.: 1991)*,
1609 *13*(11), 1251–1256. <https://doi.org/10.1093/cercor/bhg092>
- 1610 Palidis, D. J., Cashaback, J. G. A., & Gribble, P. L. (2019). Neural signatures of reward and
1611 sensory error feedback processing in motor learning. *Journal of Neurophysiology*, *121*(4),
1612 1561–1574. <https://doi.org/10.1152/jn.00792.2018>
- 1613 Pekny, S. E., Izawa, J., & Shadmehr, R. (2015). Reward-dependent modulation of movement
1614 variability. *The Journal of Neuroscience: The Official Journal of the Society for*
1615 *Neuroscience*, *35*(9), 4015–4024. <https://doi.org/10.1523/JNEUROSCI.3244-14.2015>
- 1616 Polich, J. (2007). Updating P300: An Integrative Theory of P3a and P3b. *Clinical*
1617 *Neurophysiology: Official Journal of the International Federation of Clinical*
1618 *Neurophysiology*, *118*(10), 2128–2148. <https://doi.org/10.1016/j.clinph.2007.04.019>
- 1619 Quattrocchi, G., Monaco, J., Ho, A., Irmen, F., Strube, W., Ruge, D., Bestmann, S., & Galea, J.
1620 M. (2018). Pharmacological Dopamine Manipulation Does Not Alter Reward-Based
1621 Improvements in Memory Retention during a Visuomotor Adaptation Task. *ENeuro*,
1622 *5*(3). <https://doi.org/10.1523/ENEURO.0453-17.2018>

- 1623 Ragazzoni, A., Di Russo, F., Fabbri, S., Pesaresi, I., Di Rollo, A., Perri, R. L., Barloscio, D.,
1624 Bocci, T., Cosottini, M., & Sartucci, F. (2019). “Hit the missing stimulus”. A
1625 simultaneous EEG-fMRI study to localize the generators of endogenous ERPs in an
1626 omitted target paradigm. *Scientific Reports*, 9(1), 3684. [https://doi.org/10.1038/s41598-](https://doi.org/10.1038/s41598-019-39812-z)
1627 019-39812-z
- 1628 Reynolds, J. N. J., & Wickens, J. R. (2002). Dopamine-dependent plasticity of corticostriatal
1629 synapses. *Neural Networks*, 15(4), 507–521. [https://doi.org/10.1016/S0893-](https://doi.org/10.1016/S0893-6080(02)00045-X)
1630 6080(02)00045-X
- 1631 Rothenhoefer, K. M., Costa, V. D., Bartolo, R., Vicario-Feliciano, R., Murray, E. A., &
1632 Averbeck, B. B. (2017). Effects of Ventral Striatum Lesions on Stimulus-Based versus
1633 Action-Based Reinforcement Learning. *The Journal of Neuroscience: The Official*
1634 *Journal of the Society for Neuroscience*, 37(29), 6902–6914.
1635 <https://doi.org/10.1523/JNEUROSCI.0631-17.2017>
- 1636 Rouder, J. N., Morey, R. D., Speckman, P. L., & Province, J. M. (2012). Default Bayes factors
1637 for ANOVA designs. *Journal of Mathematical Psychology*, 56(5), 356–374.
1638 <https://doi.org/10.1016/j.jmp.2012.08.001>
- 1639 Russek, E. M., Momennejad, I., Botvinick, M. M., Gershman, S. J., & Daw, N. D. (2017).
1640 Predictive representations can link model-based reinforcement learning to model-free
1641 mechanisms. *PLoS Computational Biology*, 13(9), e1005768.
1642 <https://doi.org/10.1371/journal.pcbi.1005768>
- 1643 Sabeti, M., Katebi, S. D., Rastgar, K., & Azimifar, Z. (2016). A multi-resolution approach to
1644 localize neural sources of P300 event-related brain potential. *Computer Methods and*
1645 *Programs in Biomedicine*, 133, 155–168. <https://doi.org/10.1016/j.cmpb.2016.05.013>

- 1646 Sambrook, T. D., & Goslin, J. (2015). A neural reward prediction error revealed by a meta-
1647 analysis of ERPs using great grand averages. *Psychological Bulletin*, *141*(1), 213–235.
1648 <http://dx.doi.org.proxy1.lib.uwo.ca/10.1037/bul0000006>
- 1649 Sambrook, T. D., & Goslin, J. (2016). Principal components analysis of reward prediction errors
1650 in a reinforcement learning task. *NeuroImage*, *124*, 276–286.
1651 <https://doi.org/10.1016/j.neuroimage.2015.07.032>
- 1652 Sambrook, T. D., Hardwick, B., Wills, A. J., & Goslin, J. (2018). Model-free and model-based
1653 reward prediction errors in EEG. *NeuroImage*, *178*, 162–171.
1654 <https://doi.org/10.1016/j.neuroimage.2018.05.023>
- 1655 Santesso, D. L., Evins, A. E., Frank, M. J., Schetter, E. C., Bogdan, R., & Pizzagalli, D. A.
1656 (2009). Single dose of a dopamine agonist impairs reinforcement learning in humans:
1657 Evidence from event-related potentials and computational modeling of striatal-cortical
1658 function. *Human Brain Mapping*, *30*(7), 1963–1976.
- 1659 Schultz, W., Dayan, P., & Montague, P. R. (1997). A neural substrate of prediction and reward.
1660 *Science*, *275*(5306), 1593–1599.
- 1661 Schutte, I., Deschamps, P. K. H., van Harten, P. N., & Kenemans, J. L. (2020). Dopaminergic
1662 and noradrenergic manipulation of anticipatory reward and probability event-related
1663 potentials. *Psychopharmacology*, *237*(7), 2019–2030. [https://doi.org/10.1007/s00213-](https://doi.org/10.1007/s00213-020-05515-x)
1664 [020-05515-x](https://doi.org/10.1007/s00213-020-05515-x)
- 1665 Shadmehr, R., Smith, M. A., & Krakauer, J. W. (2010). Error correction, sensory prediction, and
1666 adaptation in motor control. *Annual Review of Neuroscience*, *33*, 89–108.
1667 <https://doi.org/10.1146/annurev-neuro-060909-153135>

- 1668 Shahar, N., Moran, R., Hauser, T. U., Kievit, R. A., McNamee, D., Moutoussis, M., NSPN
1669 Consortium, & Dolan, R. J. (2019). Credit assignment to state-independent task
1670 representations and its relationship with model-based decision making. *Proceedings of*
1671 *the National Academy of Sciences of the United States of America*, 116(32), 15871–
1672 15876. <https://doi.org/10.1073/pnas.1821647116>
- 1673 Sharp, M. E., Foerde, K., Daw, N. D., & Shohamy, D. (2016). Dopamine selectively remediates
1674 “model-based” reward learning: A computational approach. *Brain: A Journal of*
1675 *Neurology*, 139(Pt 2), 355–364. <https://doi.org/10.1093/brain/awv347>
- 1676 Shmuelof, L., Huang, V. S., Haith, A. M., Delnicki, R. J., Mazzoni, P., & Krakauer, J. W.
1677 (2012). Overcoming motor “forgetting” through reinforcement of learned actions. *The*
1678 *Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 32(42),
1679 14617–14621. <https://doi.org/10.1523/JNEUROSCI.2184-12.2012>
- 1680 Sidarta, A., Vahdat, S., Bernardi, N. F., & Ostry, D. J. (2016). Somatic and Reinforcement-Based
1681 Plasticity in the Initial Stages of Human Motor Learning. *The Journal of Neuroscience:*
1682 *The Official Journal of the Society for Neuroscience*, 36(46), 11682–11692.
1683 <https://doi.org/10.1523/JNEUROSCI.1767-16.2016>
- 1684 Sidarta, A., van Vugt, F. T., & Ostry, D. J. (2018). Somatosensory working memory in human
1685 reinforcement-based motor learning. *Journal of Neurophysiology*, 120(6), 3275–3286.
1686 <https://doi.org/10.1152/jn.00442.2018>
- 1687 Sing, G. C., & Smith, M. A. (2010). Reduction in Learning Rates Associated with Anterograde
1688 Interference Results from Interactions between Different Timescales in Motor
1689 Adaptation. *PLoS Computational Biology*, 6(8).
1690 <https://doi.org/10.1371/journal.pcbi.1000893>

- 1691 Singh, P., Lenka, A., Stezin, A., Jhunjhunwala, K., Pal, P. K., Ghosal, A., & Murthy, A. (2019).
1692 Basal ganglia contributions during the learning of a visuomotor rotation: Effect of
1693 dopamine, deep brain stimulation and reinforcement. *The European Journal of*
1694 *Neuroscience*, 50(8), 3349–3364. <https://doi.org/10.1111/ejn.14494>
- 1695 Smith, M. A., & Shadmehr, R. (2005). Intact Ability to Learn Internal Models of Arm Dynamics
1696 in Huntington’s Disease But Not Cerebellar Degeneration. *Journal of Neurophysiology*,
1697 93(5), 2809–2821. <https://doi.org/10.1152/jn.00943.2004>
- 1698 Sohn, Y. H., Kim, G. W., Huh, K., & Kim, J. S. (1998). Dopaminergic influences on the P300
1699 abnormality in Parkinson’s disease. *Journal of the Neurological Sciences*, 158(1), 83–87.
1700 [https://doi.org/10.1016/s0022-510x\(98\)00102-6](https://doi.org/10.1016/s0022-510x(98)00102-6)
- 1701 Soltani, M., & Knight, R. T. (2000). Neural origins of the P300. *Critical Reviews in*
1702 *Neurobiology*, 14(3–4), 199–224.
- 1703 Stanzione, P., Fattapposta, F., Giunti, P., D’Alessio, C., Tagliati, M., Affricano, C., & Amabile,
1704 G. (1991). P300 variations in parkinsonian patients before and during dopaminergic
1705 monotherapy: A suggested dopamine component in P300. *Electroencephalography and*
1706 *Clinical Neurophysiology*, 80(5), 446–453. [https://doi.org/10.1016/0168-5597\(91\)90093-](https://doi.org/10.1016/0168-5597(91)90093-d)
1707 [d](https://doi.org/10.1016/0168-5597(91)90093-d)
- 1708 Stanzione, P., Fattapposta, F., Tagliati, M., D’Alessio, C., Marciani, M. G., Foti, A., & Amabile,
1709 G. (1990). Dopaminergic pharmacological manipulations in normal humans confirm the
1710 specificity of the visual (PERG-VEP) and cognitive (P300) electrophysiological
1711 alterations in Parkinson’s disease. *Electroencephalography and Clinical*
1712 *Neurophysiology. Supplement*, 41, 216–220. [https://doi.org/10.1016/b978-0-444-81352-](https://doi.org/10.1016/b978-0-444-81352-7.50026-1)
1713 [7.50026-1](https://doi.org/10.1016/b978-0-444-81352-7.50026-1)

- 1714 Swainson, R., Rogers, R. D., Sahakian, B. J., Summers, B. A., Polkey, C. E., & Robbins, T. W.
1715 (2000). Probabilistic learning and reversal deficits in patients with Parkinson's disease or
1716 frontal or temporal lobe lesions: Possible adverse effects of dopaminergic medication.
1717 *Neuropsychologia*, 38(5), 596–612. [https://doi.org/10.1016/s0028-3932\(99\)00103-7](https://doi.org/10.1016/s0028-3932(99)00103-7)
- 1718 Synofzik, M., Lindner, A., & Thier, P. (2008). The cerebellum updates predictions about the
1719 visual consequences of one's behavior. *Current Biology: CB*, 18(11), 814–818.
1720 <https://doi.org/10.1016/j.cub.2008.04.071>
- 1721 Takeshita, S., & Ogura, C. (1994). Effect of the dopamine D2 antagonist sulpiride on event-
1722 related potentials and its relation to the law of initial value. *International Journal of*
1723 *Psychophysiology: Official Journal of the International Organization of*
1724 *Psychophysiology*, 16(1), 99–106. [https://doi.org/10.1016/0167-8760\(94\)90046-9](https://doi.org/10.1016/0167-8760(94)90046-9)
- 1725 Tanaka, H., Sejnowski, T. J., & Krakauer, J. W. (2009). Adaptation to Visuomotor Rotation
1726 Through Interaction Between Posterior Parietal and Motor Cortical Areas. *Journal of*
1727 *Neurophysiology*, 102(5), 2921–2932. <https://doi.org/10.1152/jn.90834.2008>
- 1728 Taylor, J. A., Krakauer, J. W., & Ivry, R. B. (2014). Explicit and Implicit Contributions to
1729 Learning in a Sensorimotor Adaptation Task. *Journal of Neuroscience*, 34(8), 3023–
1730 3032. <https://doi.org/10.1523/JNEUROSCI.3619-13.2014>
- 1731 Taylor, Jordan A., Klemfuss, N. M., & Ivry, R. B. (2010). An explicit strategy prevails when the
1732 cerebellum fails to compute movement errors. *Cerebellum (London, England)*, 9(4), 580–
1733 586. <https://doi.org/10.1007/s12311-010-0201-x>
- 1734 Therrien, A. S., & Bastian, A. J. (2015). Cerebellar damage impairs internal predictions for
1735 sensory and motor function. *Current Opinion in Neurobiology*, 33, 127–133.
1736 <https://doi.org/10.1016/j.conb.2015.03.013>

- 1737 Therrien, A. S., Wolpert, D. M., & Bastian, A. J. (2016). Effective reinforcement learning
1738 following cerebellar damage requires a balance between exploration and motor noise.
1739 *Brain*, 139(1), 101–114. <https://doi.org/10.1093/brain/awv329>
- 1740 Torta, D. M. E., Castelli, L., Zibetti, M., Lopiano, L., & Geminiani, G. (2009). On the role of
1741 dopamine replacement therapy in decision-making, working memory, and reward in
1742 Parkinson’s disease: Does the therapy-dose matter? *Brain and Cognition*, 71(2), 84–91.
1743 <https://doi.org/10.1016/j.bandc.2009.04.003>
- 1744 Tseng, Y., Diedrichsen, J., Krakauer, J. W., Shadmehr, R., & Bastian, A. J. (2007). Sensory
1745 Prediction Errors Drive Cerebellum-Dependent Adaptation of Reaching. *Journal of*
1746 *Neurophysiology*, 98(1), 54–62. <https://doi.org/10.1152/jn.00266.2007>
- 1747 van der Helden, J., Boksem, M. A. S., & Blom, J. H. G. (2010). The importance of failure:
1748 Feedback-related negativity predicts motor learning efficiency. *Cerebral Cortex (New*
1749 *York, N.Y.: 1991)*, 20(7), 1596–1603. <https://doi.org/10.1093/cercor/bhp224>
- 1750 van der Kooij, K., & Smeets, J. B. J. (2019). Reward-based motor adaptation can generalize
1751 across actions. *Journal of Experimental Psychology: Learning, Memory, and Cognition*,
1752 45(1), 71–81. <https://doi.org/10.1037/xlm0000573>
- 1753 Vezoli, J., & Procyk, E. (2009). Frontal feedback-related potentials in nonhuman primates:
1754 Modulation during learning and under haloperidol. *The Journal of Neuroscience: The*
1755 *Official Journal of the Society for Neuroscience*, 29(50), 15675–15683.
1756 <https://doi.org/10.1523/JNEUROSCI.4943-09.2009>
- 1757 Vo, A., Seergobin, K. N., & MacDonald, P. A. (2017). Effects of levodopa on stimulus-response
1758 learning versus response selection in healthy young adults. *Behavioural Brain Research*,
1759 317, 553–561. <https://doi.org/10.1016/j.bbr.2016.10.019>

- 1760 Vo, A., Seergobin, K. N., & MacDonald, P. A. (2018). Independent effects of age and levodopa
1761 on reversal learning in healthy volunteers. *Neurobiology of Aging*, *69*, 129–139.
1762 <https://doi.org/10.1016/j.neurobiolaging.2018.05.014>
- 1763 Vo, A., Seergobin, K. N., Morrow, S. A., & MacDonald, P. A. (2016). Levodopa impairs
1764 probabilistic reversal learning in healthy young adults. *Psychopharmacology*, *233*(14),
1765 2753–2763. <https://doi.org/10.1007/s00213-016-4322-x>
- 1766 Walsh, M. M., & Anderson, J. R. (2012). Learning from experience: Event-related potential
1767 correlates of reward processing, neural adaptation, and behavioral choice. *Neuroscience*
1768 *and Biobehavioral Reviews*, *36*(8), 1870–1884.
1769 <https://doi.org/10.1016/j.neubiorev.2012.05.008>
- 1770 Wang, J. X., Kurth-Nelson, Z., Kumaran, D., Tirumala, D., Soyer, H., Leibo, J. Z., Hassabis, D.,
1771 & Botvinick, M. (2018). Prefrontal cortex as a meta-reinforcement learning system.
1772 *Nature Neuroscience*, *21*(6), 860–868. <https://doi.org/10.1038/s41593-018-0147-8>
- 1773 Warren, C. M., Hyman, J. M., Seamans, J. K., & Holroyd, C. B. (2015). Feedback-related
1774 negativity observed in rodent anterior cingulate cortex. *Journal of Physiology-Paris*,
1775 *109*(1), 87–94. <https://doi.org/10.1016/j.jphysparis.2014.08.008>
- 1776 Watabe-Uchida, M., Eshel, N., & Uchida, N. (2017). Neural Circuitry of Reward Prediction
1777 Error. *Annual Review of Neuroscience*, *40*, 373–394. [https://doi.org/10.1146/annurev-
1778 neuro-072116-031109](https://doi.org/10.1146/annurev-neuro-072116-031109)
- 1779 Wetzels, R., Matzke, D., Lee, M. D., Rouder, J. N., Iverson, G. J., & Wagenmakers, E.-J. (2011).
1780 Statistical Evidence in Experimental Psychology: An Empirical Comparison Using 855 t
1781 Tests. *Perspectives on Psychological Science: A Journal of the Association for*
1782 *Psychological Science*, *6*(3), 291–298. <https://doi.org/10.1177/1745691611406923>

- 1783 Wolpert, D. M., Ghahramani, Z., & Jordan, M. I. (1995). An internal model for sensorimotor
1784 integration. *Science*, 269(5232), 1880–1882. <https://doi.org/10.1126/science.7569931>
- 1785 Wong, A. L., Marvel, C. L., Taylor, J. A., & Krakauer, J. W. (2019). Can patients with cerebellar
1786 disease switch learning mechanisms to reduce their adaptation deficits? *Brain: A Journal*
1787 *of Neurology*, 142(3), 662–673. <https://doi.org/10.1093/brain/awy334>
- 1788 Wunderlich, K., Smittenaar, P., & Dolan, R. J. (2012). Dopamine enhances model-based over
1789 model-free choice behavior. *Neuron*, 75(3), 418–424.
1790 <https://doi.org/10.1016/j.neuron.2012.03.042>
- 1791